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PURIFICATION AND CHARACTERIZATION OF BLOOD ASPIRIN 
HYDROLASE 
 
GANG ZHOU 
 
ABSTRACT 
Aspirin prophylaxis suppresses major adverse cardiovascular events, but its 
turnover in blood is rapid, which limits its inhibitory effects on platelet 
cyclooxygenase and thrombosis. Inter-individual variability of platelet responses to 
aspirin clinically presents as treatment failure, and this increasing clinical 
phenomenon is frequently named aspirin “resistance”. However, the molecular 
mechanisms behind this are unclear. Blood aspirin hydrolases are believed to control 
aspirin survival in vivo, but the identity of the circulating enzyme(s) that hydrolyzes 
aspirin remains unknown.  
In this thesis, blood aspirin hydrolases were identified and characterized. The 
relationship between blood aspirin hydrolases and aspirin efficacy was investigated.  
RP-HPLC analysis of the product salicylic acid with an internal standard showed 
plasma hydrolysis of aspirin varied 12-fold variation among 2,275 individuals.  
Genome-wide association analysis using serum aspirin hydrolytic activity from 2,275 
individuals showed a genetic component to aspirin hydrolytic variation, and that only 
BChE significantly associated to aspirin variation. However, plasma from an 
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individual with an inactivating point mutation in BChE effectively hydrolyzed aspirin. 
A non-BChE aspirin hydrolase was found in plasma, which can be distinguished from 
BChE by procainamide and oxidized ATP. Erythrocyte aspirin hydrolase was purified 
by 1400-fold and type I PAF acetylhydrolase was identified as a candidate aspirinase 
by mass spectrometry. Recombinant PAFAH1B2 hydrolyzed aspirin and aspirin was 
effectively hydrolyzed in cells ectopically expressing PAFAH1B2 and PAFAH1B3. 
Type I PAFAH also accounts for non-BChE plasma aspirin hydrolytic activity. Both 
plasma and erythrocytes were found modulated aspirin efficacy significantly, which 
varied by aspirin hydrolytic activity variation. 
I hope my work in this thesis will help to understand aspirin “resistance” and 
shed light on personalized medicine of aspirin.  
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CHAPTER I 
1. INTRODUCTION 
1.1. A history of aspirin 
Human beings are known to have more than 100,000 years of history, but 
knowing therapies using naturally occurring plants and derivatives of plants is just 
about thousands years old. Aspirin is the oldest and most widely used medicine in the 
world. Almost everyone knows or has the experience of taking aspirin, but not 
everyone knows its history. People in early days, especially the Assyrians and the 
ancient Egyptians almost 2,000 years ago, recorded using willow bark and leaves to 
alleviate arthritis pain (Jack 1997). However, at that time they were unaware of the 
reasons behind this. About 100 years ago, Hippocrates, the Greek physician, 
described and documented that willow bark has analgesic function. The anti-
inflammatory and anti-pyretic effects of willow bark were first documented by Galen. 
However, Edward Stone is generally regarded as the first person who gave the 
scientific description of willow bark in clinical use, and he also pointed out the anti-
malarial effects of willow bark (Jack 1997; Hawkey 2005).  
With rapid development of chemistry in the 18th and 19th centuries, Henri 
Leroux, a French Pharmacologist, and Raffaele Piria, an Italian Chemist, isolated a 
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functional compound from willow bark in 1826. Almost at the same time, the same 
compound was purified by Johann Buchner (Jack 1997), and was named salicin 
(Figure 1), which means “willow” in Latin. Purification and isolation of salicin from 
willow barks was optimized at a later time. In the meantime, physicians started 
prescribing salicin as a drug to relieve fever and pain. In 1876, Thomas Maclagan, a 
Dundee physician, published a paper to report the beneficial effects of salicin in 
treating patients who had rheumatism in the well reputed British Journal “The Lancet” 
(Maclagan 1876). Ten years later, Herman Kolbe, a German Chemist, first 
synthesized salicylic acid from salicin. German chemist, Felix Hoffmann, first 
synthesized according to available records and commercialized the acetylsalicylic 
acid in 1897 (Jack 1997; Miner and Hoffhines 2007; Schrör 2009). Because his 
farther hated taking salicylic acid, which irritated his gut, he wanted to make a 
substitute for salicylic acid.  And finally he was able to create acetylsalicylic acid 
from salicylic acid (Figure 2), which was named aspirin. At that time, he worked at 
Bayer, and with a pharmacist, Heinrich Dreser, together they did the pharmaceutical 
and clinical trial for aspirin. On 23 January 1899 they decided to give this compound 
the brand name “Aspirin” and finally, on March 6th 1899, it was registered at the 
Kaiserlichen Patentsamt, Berlin and received a patent. And then Bayer put aspirin on 
the market as an analgesic drug for rheumatism (Hawkey 2005). Aspirin is the first 
synthesized drug and its development is also regarded as the milestone of the modern 
pharmaceutical industry.  
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Figure 1. Structure of Salicin 
 
 
Figure 2. Structures of Salicylic acid and Aspirin. Aspirin has an acetyl group, 
which make aspirin different from salicylic acid. 
 
Due to better tolerance to the stomach over salicylic acid, aspirin quickly 
became popular and was widely used all over the world as a substitute for salicylic 
acid. Until now aspirin still is a famous medicine, although it has side effects, such as 
gut bleeding. Structurally, acetyl group is the only difference of aspirin from salicylic 
acid. And because of this, aspirin has a novel ability to prevent cardiovascular events 
(Weiss 2003), which is first discovered by Dr. Lawrence L. Craven. However, 
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patients taking aspirin as a prophylactic agent were still subject to heart attacks 
(Helgason, Bolin et al. 1994; Bradbury 2002).  
Despite its routine use, the mechanisms of aspirin action were poorly 
understood. At meantime, Sir John Vane and Priscilla Piper were studying the 
inhibitory affects of aspirin on the biosynthesis of prostaglandins, which eventually 
explained how aspirin works. In 1982, John Vane won the Nobel Prize in Physiology 
or Medicine because of his great work on aspirin. However, the aspirin story is not 
over. It was found that aspirin possibly has therapeutic value to a variety of diseases, 
including dementia and certain cancers. But the mechanisms behind these new 
findings are not still clear and needed further investigation, although aspirin is used as 
a prophylactic agent. 
1.2. Properties and functions of aspirin 
Chemically synthesized aspirin is a white powder with better solubility in 
ethanol (20%) than in water (0.3%). The solubility of aspirin in aqueous media largely 
depends on pH value (Figure 3).  When the pH is around 7, there is a minor variation 
in aspirin hydrolysis. This property makes measurement of aspirin hydrolysis 
reproducible at physiological pH.  
 
 
5 
 
 
Figure 3. Aspirin (1.5mM) hydrolysis in aqueous solution at different pH. 
(Horsch 1979). Numbers in the figure are pH values. (42°C) 
 
Aspirin has multiple beneficial effects, such as analgesic, antipyretic, and anti-
inflammatory functions. The reason for aspirin’s ability to display multiple effects is 
not clear. Once aspirin gets into blood, it is hydrolyzed and becomes a mixture of 
several components, intact aspirin, salicylic acids, their metabolites, and acetic acid, 
which give aspirin pharmacological activities via both intact molecules and salicylic 
acids. This may affect certain cellular targets and signaling pathways. The main 
functions of aspirin as mentioned above focused on three aspects: 1) the original 
clinical function as a classic Non-Steroidal Anti-Inflammatory Drug (NSAID) is 
analgesic and antipyretic activity; 2) the anti-inflammatory effect is also a valuable 
clinical function. 3) the effect of aspirin in anti-platelet function. Sir John Vane in 
1971 first gave the pharmacological explanation for aspirin’s multiple actions as 
blocking prostaglandin biosynthesis (Vane 1971). Because of these important findings, 
he was awarded Nobel Prize in Physiology and Medicine in 1982. His findings gave 
solid evidence that blocking prostaglandins production is the basis reason of the 
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analgesic, anti-inflammatory and anti-platelet effects. Acetylating of salicylic acid 
added a new property to aspirin (Figure 2) not showing in salicylates, inhibition of 
platelet function. Cardiovascular disease prevention effects of aspirin stems from its 
anti-platelet function. Aspirin’s anti-platelet effects are believed to be due to 
acetylation of cyclooxygenase-1 (COX-1) at 530 serine residue (Roth and Majerus 
1975). The acetylation irreversibly inhibits COX-1 in anucleated platelets, thereby 
blocking thromboxane A2 production and suppressing platelet activation. Salicylic 
acid, the metabolite of aspirin hydrolysis, is reported to inhibit COX-1 as well, but the 
potency of salicylic acid in inhibiting COX-1 is very low when compared to that of 
aspirin and it also varies with albumin concentrations (Warner, Vojnovic et al. 2006). 
In addition to these major functions, there are other reported effects of aspirin. 
Researchers are still making efforts to find novel mechanisms for aspirin through 
further understanding of its molecular action.  
1.3. Metabolism of aspirin 
The metabolism of aspirin in vivo involves two distinct processes. The two 
processes are thought to occur independently to each other. Pharmacologically the 
two processes are called phase I and II biotransformation. Phase I refers to aspirin 
losing its acetyl group. In this phase, aspirin is undergoing hydrolysis and nonspecific 
transfering of the acetyl group and produces salicylic acid. Phase II biotransformation 
refers to the further transforms of salicylic acid. In this phase, salicylic acid is 
conjugated to other soluble molecules, which can be eliminated by kidney. Different 
biological significant enzymes may involve in the two independent processes.  
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Aspirin after oral administration is metabolized in stomach, liver, and blood 
and broken down to salicylic acid and acetic acid. Blood is believed to be the major 
place where aspirin gets hydrolyzed (70%) after oral administration. The half-life of 
aspirin in vivo is only 15-20 minutes (Pedersen and FitzGerald 1984), while the half-
life of salicylate, aspirin hydrolysis product, under therapeutic doses is 2-4h, but can 
vary with increased doses (Done 1960). Approximately 80% of salicylates are 
conjugated with glucuronic acid forming phenolic glucuronide and salicyl CoA and 
with glycine forming salicyluric acid in the liver (Figure 4). Salicyliates can be 
hydroxylated to gentisic acid as well. However, only a limited amount of salicylic 
acid is metabolized by these pathways.  Given large doses of salicylic acid, the 
kinetics of metabolism will switch from first order to zero order (Levy and Tsuchiya 
1972). 
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Figure 4. Catabolism of aspirin in vivo. Aspirin is catabolized to salicylic acid and 
then to salicyluric acid. 
 
Salicylic acid is mainly excreted by kidney; 75% as salicyluric acid; 10% as 
free salicylic acid; 10% as salicylic phenol; 5% as acyl glucuronides; and gentisic acid 
is less than 1%.  When an adult ingests less than 250 mg salicylic acid, half-life of 
salicylic acid will be 2-3 hours and all metabolic processes are in first order kinetics 
(Hartwig-Otto 1983). When more than 4g salicylic acid is ingested, because the 
salicyl phenolic glucuronide and salicyluric acid biotransformatic pathways become 
saturated, the half-life of salicylates increases to 15-30 hours (Levy 1965). Because 
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when pH value is above 6 in urine, excretion of salicylic acid by kidney becomes 
more important when the biotransformatic pathways become saturated (Hollister and 
Levy 1965). So urinary alkalinization is usually a measure used to increase 
elimination of over loaded salicylates. 
 
1.4. Platelets 
Platelets, or thrombocytes, are small and anucleate cells. They have a diameter 
of 2–3 µm. Platelets are derived from megakaryocytes.  Platelets have a short lifespan 
in circulation, which is normally 7 to 10 days in average before being removed by the 
hemopoietic tissue spleen. Platelets have a single peripheral microtubule coil 
(Fitzgerald, Poncz et al. 1987) and a subplasmalemmal membrane skeleton of actin 
(Zimrin, Eisman et al. 1988). Platelets circulate in blood, and participate in hemostasis 
and blood clotting. They also produce growth factors.  
 
1.4.1. Platelet activation 
Resting platelets do not interact with other cells. However, they are ready to 
respond and react if they are subjected to certain stimuli. The reaction of platelets is 
protective, but sometime it is destructive when losing control. When underlying 
connective tissue elements such as collagen are exposed during vascular damage, 
platelets around the lesion will be activated, which will induce a sequence of events 
including adhesion to collagen matrix, a change of platelet morphology from a disk to 
 
 
10 
 
an irregular sphere with filopodia, granule secretion, and aggregate formation. These 
events are usually referred to as adhesion, shape change, secretion, and aggregation.   
Because of their roles in physiology, platelets are eazy to be activated. They 
can be stimulated by several agonists, such as collagen, von Willebrand factor (vWF), 
fibrinogen, thrombin, Adenosine diphosphate (ADP), epinephrine, vasopressin, 
platelet activating factor (PAF), and thromboxane A2 (TxA2). These agonists are 
commonly classified as strong and weak. In order to respond quickly to vascular and 
tissue damage, platelets can amplify stimulating signals to self-reinforce reactions. 
This is a positive feedback loop, which once started cannot be stopped and also more 
and more strong. Two intracellular pathways are involved in platelet activation. One 
is phosphoinositide pathway, the other is eicosanoid pathway (Ronald Hoffman; 
Edward J. Benz 1991). In the phosphoinositide pathway after stimulation 
phospholipase C gamma (PLC) cleaves phosphatidylinositol 4, 5-bisphosphate (PIP2) 
in platelets or other cells to two second messengers, inositol 1, 4, 5-trisphosphate (1, 
4, 5-IP3) and diacylglycerol (DAG). These second messengers increase intracellular 
calcium concentration which then stimulates other signaling events including Protein 
Kinase C. In eicosanoid pathway, membrane phospholipid hydrolysis is catalyzed by 
phospholipase A2 to liberate arachidonate, which is then further metabolized to PGH2 
by cyclooxygenase-1 or 2 and is then catalyzed by thromboxane synthase in platelets 
to thromboxane A2 (TxA2), which reacts with its specific receptors to enhance the 
reaction. Because TxA2 can easily diffuse across the plasma membrane of platelet, it 
can serve as a lipid mediator among platelets as well as within platelets. The 
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metabolism pathway of arachidonate converting to TxA2 is selectively inhibited by 
nonsteroidal anti-inflammatory drugs (NSAID), especially aspirin. 
The final consequence of platelet activation is platelet aggregation. There 
include a glycoprotein IIb-IIIa complex that belongs to a family of adhesive protein 
receptors called integrins on the plasma membrane, which serve as platelet fibrinogen 
receptors. Platelets form aggregates which need fibrinogen to bridge adjacent 
platelets. Ex vivo platelet aggregation is usually used to examine platelet function by 
monitoring light transmission for washed platelets or platelet rich plasma (PRP), or 
the electrode impedance of whole blood.   
 
1.4.2. Platelet- activating factor (PAF) 
Platelet activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glycero-3-
phosphocholine) is one of the molecules produced by cells in and around the vascular 
space which stimulates platelet activation. It was first described as a platelet activator 
released from stimulated mast cells, although its biological effects are beyond platelet 
activation (Braquet, Bourgain et al. 1989; Page and Abbott 1989). PAF is produced by 
neutrophils, macrophages, eosinophils, and endothelial cells, but minimally by human 
platelets (Braquet, Touqui et al. 1987; Chao and Olson 1993; Ishii and Shimizu 2000). 
PAF is the first bioactive phospholipid characterized to have an effect on platelets 
(Benveniste, Tence et al. 1979; Blank, Snyder et al. 1979; Demopoulos, Pinckard et al. 
1979), so it has attracted a lot of attention.  
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As a potent mediator, PAF can elicit significant biological responses at 
nanomolar concentrations both in vivo and ex vivo (Snyder 1995). PAF activates 
platelets and causes aggregation and secretion at concentrations ranging from 10 to 
100 nM (Lapetina and Siegel 1983; MacIntyre and Pollock 1983; Kloprogge and 
Akkerman 1984). Binding studies with radiolabeled PAF are complicated by the 
ability of many cells, including platelets, to take up and metabolize the mediator 
(Kloprogge and Akkerman 1984; Braquet, Touqui et al. 1987; Valone 1988). But the 
dissociation constants that have been reported are at least as low as the concentrations 
required to activate platelets (Kloprogge and Akkerman 1984; Ukena, Dent et al. 1988; 
Valone 1988). PAF has been shown to cause shape change, phosphoinositide 
hydrolysis and protein phosphorylation in platelets and to increase the cytosolic free 
calcium concentration (Lapetina and Siegel 1983; MacIntyre and Pollock 1983; 
Kloprogge and Akkerman 1984). These responses appear to involve one or more G 
proteins (Houslay, Bojanic et al. 1986; Hwang, Lam et al. 1986). When platelets are 
stimulated, PAF will accumulate on the membrane surface and works as a juxtacrine 
lipid mediator to start various thrombotic events (Ninio, Leyravaud et al. 1991; Zhou, 
Javors et al. 1992). Exogenous recombinant PAF acetylhydrolase (Ostrovsky, King et 
al. 1998) or PAF receptor antagonists (Weber and Springer 1997) demonstrated that 
NF-κB translocates to the nucleus assisted by PAF and alters gene expression 
(Weyrich, McIntyre et al. 1995). These effects of PAF are generally accepted as 
acting through a single, unique and specific receptor, the PAF receptor (Ishii and 
 
 
13 
 
Shimizu 2000), which was identified taking the advantage of the development of PAF 
antagonists and was first clone by Honda (Honda, Nakamura et al. 1991). 
1.4.3. Platelet -activating factor acetylhydrolases (PAF-AHs) 
The acetyl group of PAF can be hydrolyzed by a family of enzymes called 
PAF-acetylhydrolases. In general there are two categories of platelet-activating factor 
acetylhydrolases (PAFAH): plasma or secreted type, and intracellular or non-secreted 
type. Macrophages are the major source of PAFAH, which has same properties to  
plasma form PAFAH (Stafforini, Elstad et al. 1990). Another work confirmed this 
conclusion. By using northern blot analysis, mRNA of PAF acetylhydrolase was 
found expressed in lymphatic tissues, such as tonsil, thymus, and spleen (Tjoelker, 
Wilder et al. 1995). It was reported that most plasma PAFAH is associated with low-
density lipoproteins (LDLs) and small part with high-density lipoproteins (HDLs) 
(Stremler, Stafforini et al. 1991) (Stafforini, McIntyre et al. 1987). Specific subtypes 
of HDL (very high-density lipoprotein-1 or VHDL-1) and LDL (small, dense LDL or 
LDL-5) carry most of PAFAH activity in human plasma (Tselepis, Dentan et al. 
1995). However, the activities of plasma PAFAH associated with lipoproteins are 
different.  HDL activity hydrolyzes PAF much slower than LDL activity (Stafforini, 
Carter et al. 1989). It was explained as that activity of PAF acetylhydrolase depends 
on particle concentrations of lipoproteins associated with PAFAH (Blencowe, 
Hermetter et al. 1995). It has been established that PAFAH also accept other 
physiological active molecules, e.g. fragmented oxidative phospholipids, as its 
substrates (Stafforini, Prescott et al. 1996). Based on enzymatic activity categorization, 
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PAF acetylhydrolases is belong to  group VII of the phospholipases A2 (PLA2) super 
family (Dennis 1997). The plasma type PAFAH hydrolyzes phospholipids with Sn-2 
acyl chains with intermediate length including PAF, but only if they are oxidized 
including esterified isoprostanes (Stremler, Stafforini et al. 1991). Isoform II PAF 
acetylhydrolase, one of the intracellular types, accepts PAF and phospholipids 
containing longer Sn-2 acyl residues and is well characterized as an enzyme 
susceptible to oxidative stress (Hattori, Hattori et al. 1995).  
Type I PAFAH, a special intracellular type of PAFAH and a unique serine 
esterase (Hattori, Adachi et al. 1994; Ho, Swenson et al. 1997), unrelated to the other 
two types of the group VII PLA2 family (Six and Dennis 2000), is very specific for 
the Sn-2 acetyl group of phospholipids, and has less sequence homology with any 
other two types of PAFAH (Arai, Koizumi et al. 2002). Interestingly, tertiary structure 
of it resembles that of G-protein (Ho, Swenson et al. 1997). 
Type I PAF acetylhydrolase, one of the intracellular PAFAH, was initially 
purified from bovine brain (Hattori, Arai et al. 1993). PAF hydrolase from red blood 
cells was purified and found the PAFAH1B2 and PAFAH1B3 type I PAF 
acetylhydrolase abundantly express (Karasawa, Shirakura et al. 2005). This low 
molecular weight of the enzyme purified from red blood cells was found to be 
sensitive to inhibitors, such as sodium fluoride, DTNB, and 
diisopropylfluorophosphonate (Stafforini, Rollins et al. 1993). Type I PAFAH is 
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expressed in most human tissues. However, its biological functions have not been 
defined.  
The type I PAFAH is a trimmer---a heterodimer of catalytic subunits, 
PAFAH1B3 and PAFAH1B2, with a non-catalytic LIS1 subunit. PAFAH1B2 was 
characterized to be a specific serine esterase with an active site at ser47 residue that 
had some homology to PAF receptor (Hattori, Adachi et al. 1994). PAFAH1B3 is 
another catalytic subunit which plays important role in brain development (Nothwang, 
Kim et al. 2001). PAF is believed to be the physiological substrate for type I PAFAH, 
because PAF hydrolyzing activity was used to purify type I PAFAH. Anti-apoptotic 
action of PAFAH1B2 has been shown (Bonin, Ryan et al. 2004). Animal studies 
showed PAFAH1B involved in spermatogenesis (Koizumi, Yamaguchi et al. 2003; 
Yan, Assadi et al. 2003) and neuronal migration (Manya, Aoki et al. 1998). The real 
physiological function of this enzyme is still not clear.  
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1.5. Aspirin resistance  
 
Figure 5. Scientific publications on aspirin resistance. 
 
In terms of both efficacy and safety, patients have considerable heterogeneity 
in their responses to aspirin, a worldwide drug. If patients on aspirin clinically are 
present as treatment failure although taking the medicine at effective dosing (75–
325mg/day), it is frequently and specially named “aspirin resistance”, which is of 
more clinical attention recently (Figure 5). Aspirin resistance is defined generally of 
two types, but they may have overlap to each other.  “Laboratory aspirin resistance” is 
regarded as aspirin has partial to no effect on supressing platelet activation in vitro 
measured by instruments such as a platelet aggregometer; or as “clinical aspirin 
resistance” which is defined as aspirin failing to protect patients from cardiovascular 
events, which is also called as “treatment failure” (Tantry, Mahla et al. 2009). 
Platelets can be stimulated by numerous of agonists through several pathways, so it is 
not surprising for aspirin resistance. Anti-platelet drugs are usually designed to block 
a certain activating pathway, which limits their effects on complicated thrombotic 
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diseases due to so many activating pathways exist. That is why clinically using more 
than one drug to treat patients.  And another problem makes aspirin resistance more 
unpredictable. That is lacking universal standard methods to evaluate aspirin 
resistance, so the reports of aspirin resistance range from 0.4% (Tantry, Bliden et al. 
2005) to as high as 70%. The most common reason believed of  aspirin resistance is 
noncompliance (Schwartz, Schwartz et al. 2005). Other possible reasons include 
inadequate dosing (Roth and Calverley 1994), duration of other medication or therapy 
(Pulcinelli, Pignatelli et al. 2004), smoking (Macchi, Christiaens et al. 2002), variable 
reactions of individuals in aspirin pharmacodynamics and pharmacokinetics, such as 
absorption, bioavailability, metabolism, and excretion (Williams, Mutch et al. 1989; 
Akopov, Grigorian et al. 1992; Pappas, Westengard et al. 1994), alternative pathways 
of TxA2 production (Maclouf, Folco et al. 1998; Weber, Zimmermann et al. 1999), 
and TxA2 independent platelet activation pathways (Santos, Moscardo et al. 2000) 
have been also proposed. Also under disease conditions such as diabetes (de Gaetano 
2004) and hypercholesterolemia (Szczeklik, Musial et al. 2002), the anti-platelet 
effect of aspirin are impaired.  
However, the incidence of “aspirin resistance” may not really be increasing. 
Treatment failures with drugs are common phenomenon, e.g. clopidogrel resistance 
(Wiviott and Antman 2004). The large inter-individual variability may suggest that 
there are more factors affecting aspirin treatment leading to treatment failures  (Schror 
2002). People usually confuse treatment failure with aspirin working failure, 
especially when failure of clinical treatment is frequently mixed up with a failure of 
aspirin to work pharmacologically (Hennekens, Schror et al. 2004). The other 
question is that there is no universal standard or method to define aspirin resistance, 
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neither in clinical nor in the laboratory. Responses of patients with cardiovascular or 
cerebrovascular disease to aspirin are capricious. Same group of patients responded 
well to aspirin in one study, but they were found not to respond to aspirin in other 
studies (Helgason, Hoff et al. 1993; Helgason, Tortorice et al. 1993; Helgason, Bolin 
et al. 1994; Buchanan and Brister 1995; Mueller, Salat et al. 1997) (Weksler, Kent et 
al. 1985; Berglund and Wallentin 1991). Unfortunately, the term “resistance” has 
been used in articles because of its widespread acceptance, although people do not 
know what aspirin resistance really is. Aspirin resistance should be related to 
impaired aspirin effects. So aspirin resistance is classified into three distinct types 
(Figure 6) by biology and biochemistry methods (Weber, Przytulski et al. 2002). The 
first is pharmacokinetic resistance. It means that aspirin works only in vitro but not in 
vivo. Platelet activation is not inhibited by oral aspirin administration. However, when 
treating isolated platelets from the same individual with same amount of aspirin in 
vitro, both TxA2 formation and platelet aggregation are effectively inhibited. This 
indicates no treatment amount of aspirin gets into platelets, namely majority of aspirin 
is metabolized before getting in platelets. The second is pharmacodynamic resistance. 
In this type of resistance, it is more like type I, but even in vitro the same amount of 
aspirin only partially inhibits platelet activation and TxA2 production. However, by 
increasing aspirin dosage, inhibition can be completed. This suggests the sensitivity of 
targets of platelets to aspirin is impaired for some reasons. The last one is called 
pseudoresistance. This means that aspirin does work efficiently, because it blocks 
TxA2 formation completely. However, platelets are activated normally without any 
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suppression. This is not a true resistance of aspirin. It is because TxA2 independent 
pathways involves in platelet activation. From these three reasons for impairment of 
anti-platelet function of aspirin we may conclude as follow: (i) aspirin cannot reach 
the active site in sufficient amounts; (ii) the platelet activation factors are not sensitive 
to aspirin because the cellular or molecular targets of aspirin are impaired, and (iii) 
platelets are stimulated by other pathways which by pass aspirin targets (Schrör 2009). 
 
Figure 6. Types of aspirin resistance (Weber, Przytulski et al. 2002). 
There are several platelet activation pathways which bypass the primary target 
of aspirin, namely COX-1. However, these situations may be not that important, 
because most of the time collagen stimulated platelet activation is prevalent in CVD, 
which usually occurs after the endothelium damaged. The sensitivity of aspirin target, 
COX-1, due to genetic factors has been examined, but effects of mutation or 
polymorphisms in aspirin’s active site are controversial (Maree, Curtin et al. 2005; 
Lepantalo, Mikkelsson et al. 2006; Takahashi, Ushida et al. 2008). Only the 
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bioavailability reason is more common and basic problem which needs to be 
considered for all drugs. As previously showed aspirin is quickly deacetylated and 
loses its anti-platelet function in about 20 minutes in systemic circulation (Figure 7).  
Blood is the major place where about 70% of aspirin is inactivated. Thus, aspirin 
hydrolase is very important in controlling aspirin’s survival or half-life in circulation, 
but identities of aspirin hydrolases in human blood are still undefined. 
 
 
 
Figure 7. The mechanism of aspirin’s anti-platelet function. Arachidonic acid 
released from membrane by phospholipase A2 is oxidized by cyclooxygenase-1 to 
PGG2, which further modified by different enzymes in individual tissues to different 
products. Aspirin inhibits cyclooxygenase-1 irreversibly by acetylating 530-serine 
residue. 
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1.6. Aspirin esterase 
Aspirin esterases are important in controlling aspirin hydrolysis. They include 
several enzymes which can remove the acetyl group of aspirin. Enzymatic hydrolysis 
of aspirin starts in the gastrointestinal mucosa after being given orally (Levy 1978; 
Spenney 1978) and continues in liver and the portal vein (Levy 1979; Williams, 
Mutch et al. 1989), which is called the first pass effect. After the first pass effect by 
liver and gut, about 70% of aspirin reaches blood and it is metablized to salicylic acid 
by serum esterases (Rainsford, Ford et al. 1980; Seymour, Williams et al. 1984) and 
by erythrocytes (Costello and Green 1983; Costello, Caruana et al. 1984). So blood is 
the major place to hydrolyze aspirin. The half-life of aspirin in circulation is around 
15–20 min (Levy 1965; Rowland, Riegelman et al. 1972; Shen, Wanwimolruk et al. 
1991), which is mainly controlled by blood esterases. The esterases classification is a 
hard work, so there are different classifications of esterases. In 1953, by using 
different organophosphorous esters as substrates, Aldridge classified esterases as A, 
B, or C groups (Aldridge 1953). By involving inhibitors in the classification besides 
subtstrates, in 1961 Augustinsson classified esterases as cholinesterases, aryl esterases 
and carboxylesterases (Augustinsson 1961; Ali and Kaur 1983). Human plasma has 
only cholinesterases and aryl esterases, but no detectable carboxylesterases (Li, 
Sedlacek et al. 2005). Plasma albumin is also considered as an esterase (Kurono, 
Kondo et al. 1983; Sakurai, Ma et al. 2004; Yang, Bian et al. 2007; Lockridge, Xue et 
al. 2008). But this issue is controversial, in 2001, Chapuis  showed that esterase-like 
activity of serum albumin was probably due to butyrylcholinesterase contamination 
(Chapuis, Bruhlmann et al. 2001). Until now there are three esterases claimed to be 
present in human plasma that hydrolyze aspirin. They are butyrylcholinesterase 
(Morikawa, Inoue et al. 1979; Masson, Froment et al. 1998), paraoxonase-1 
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(Santanam and Parthasarathy 2007) and albumin (Morikawa, Inoue et al. 1979; 
Liyasova, Schopfer et al. 2009). But this is not widely accepted, and people still use 
the term aspirin esterase to indicate any enzyme that hydrolyses aspirin (Adebayo, 
Williams et al. 2007). 
Butyrylcholinesterase: Butyrylcholinesterase (BChE), also called plasma, 
serum or pseudo cholinesterase, is a tetrameric glycoprotein with a molecular mass of 
342 kDa. BChE gene is located on chromosome 3 at long arm, fragment 26. It is 
synthesized and secreted primarily from the liver (Lockridge, Adkins et al. 1987) and 
finally distributed in mucosa of the intestines, blood and the white matter of the 
central nervous system. Each identical subunit of BChE has an active catalytic site 
(Bergmann and Wurzel 1954). The physiological function of BChE is largely 
unknown. Human plasma aspirin hydrolytic activity and BChE activity are skewed 
and positively correlated (Adebayo, Williams et al. 2007). BChE requires Ca2+ to 
maximize its activity when catalyzing hydrolysis of its known substrates. BChE can 
hydrolyze aspirin, although it is different from other substrates in kinetics (La Du 
1971). There are several kinds of human BChE deficiencies known due to different 
genetic reasons, including FS117 first described by Liddell et al. (Liddell, Lehmann et 
al. 1962). It may have a homozygous frequency of 1:100,000. This mutation caused a 
reading frame change at the first base pair and created a stop codon (TGA) at position 
129aa. The changes would make a product of 22% of the mature protein (601aa) and 
are upstream of the serine-198 active center, which makes no detectable BChE 
activity in plasma. Clinically, these individuals appear to be normal.  
Paraoxoanase (PON):
organophosphates
 paraoxonases, a family of three isomers, PON1, PON2 
and PON3, are a group of enzymes having  hydrolytic activity. The 
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genes coding PON are located together on 7q21.3-q22.1 (Primo-Parmo, Sorenson et 
al. 1996). PON2 is intracellular and expressed widely in liver, brain, lungs, and heart, 
but not found in blood (Mochizuki, Scherer et al. 1998). Both PON1 and PON3 are 
found in blood, which may be secreted from liver (Mackness, Hallam et al. 1985; 
Reddy, Wadleigh et al. 2001), but they have different substrate specificities. PON1 is 
well investigated member in the paraoxonase family. It is a calcium dependent 
hydrolase with the ability to recognize a broad spectrum of synthetic substrates. It is 
tightly bound to plasma high density lipoproteins (HDL) and exhibits anti-oxidative 
activities, which can protect low density lipoprotein (LDL) from being oxidized. 
However, some of its properties appeared to be due to PAFAH contamination that co-
eluted with PON1 during purification (Marathe, Zimmerman et al. 2003; Kriska, 
Marathe et al. 2007). In 2007, aspirin was reported to be a substrate for PON1 
(Santanam and Parthasarathy 2007). 
The identities of the enzymes in blood that actually hydrolyze aspirin have not 
been elucidated despite they all appear to hydrolyze aspirin and to affect aspirin levels, 
although these enzymes may be factors in defining the poorly documented syndrome 
of aspirin resistance (Fitzgerald and Maree 2007; Patrono and Rocca 2007; Lev 2009).  
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CHAPTER II 
2. MATERIALS and METHODS 
 
2.1.1. Commercially available reagents:  
Chemicals: Aspirin, Salicylic acid, o-Anisic acid, Brilliant Blue R-250, 
Formic acid, Anthranilic acid, Acetaminophen, 5, 5’-Dithiobis (2-nitrobenzoic acid), 
sephadex G-100, Blue Dextran, Acetyl-β-methylcholine chloride, Adenosine 5’-
triphosphate, 4-Methylumbelliferyl acetate, Butyrylcholine chloride, S-
Butyrylthiocholine iodide, Adenosine 5’-triphosphate, periodate oxidized sodium salt, 
Adenosine 5’-triphosphate immobilized on agrose 4B, cell lysis buffer 10× (Cell 
Signaling).  
2.1.2. Antibodies:  
BChE (C-18), BChE (N-15), AGP1 (27A1), APEH (N-18), APEH (C-15), 
CD39 (BU61), and β-actin (Santa Cruz, CA); anti-PAFAH1B2 (16-30) and 
PAFAH1B3 (SAB1100319, Sigma) 
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2.2. Methods 
2.2.1. 
Aspirin (Sigma, MA) 18mg is dissolved in 1ml of methanol. 10µl of aspirin 
solution is transferred into each tube and dried under N2. Enzyme source and buffer is 
added to bring the volume to 200µl. Incubation is performed at 37℃ for 1 or 2 hours 
as stated, depending on the activity of the enzyme source. After incubation the 
reaction is stopped by adding 0.1% formic acid (200µl) and aspirin and salicylic acid 
are twice extracted by a mixture of ethyl acetate and ether (4:1, v/v) 1ml. The 
supernatant is then blown dry under N2 before being reconstituted into 500µl HPLC 
mobile phase and 100µl being injected. Then on to a 4.6 × 150mm, 5µm, Eclipse 
XDB-C8 column (ZORBAX, Agilent), mobile phase was methanol: water (40/60, 1% 
acetic acid, v/v) at a flow rate of 0.8ml/min. Aspirin and salicylic acid display 
retention times around 7 and 13 minutes (Figure 9). Standard curve was plotted to 
estimate salicylic acid produced by aspirin hydrolysis (Figure 8).  
Aspirin hdyrolytic activity assay by Reverse Phase High Performance Liquid 
Chromatography 
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Figure 8. Linear relationship between under curve area and the amount of 
Aspirin and Salicylic acid. Different amount of Aspirin and Salicylic acid (10, 50, 
100, 200, 300, 400, 500, 600, 700, 800, 900ng) were injected into HPLC. Signals 
were detected at 280nm.  
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Figure 9. Separation of Aspirin and Salicylic acid by RP-HPLC. The retention 
time of Aspirin is around 7 minutes; the retention time of Salicylic acid is around 13 
minutes. 
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2.2.2. 
In order to make quantification of salicylic acid suitable for a high throughput 
measurement of aspirin hydrolysis, I developed a faster assay using 96 well round 
bottom plates. Here, the total reaction volume was 50 µl, which contained 2mM 
aspirin. This was incubated with 10 µl enzyme source at 37℃ for 2 or 3 hours. After 
incubation the reaction was stopped and proteins were precipitated by adding 150µl 
acetonitrile containing 0.1% of formic acid. The plate was centrifuged at 4,000×g at 
4℃ for 20 min before 10µl of the supernatant was injected onto the column of an 
Agilent 1100 HPLC (2×150mm, 5µm; ODS, Phenomenex). The mobile phase was 
acetonitrile: water (40/60, v/v) containing 0.1% formic acid and flow rate was 
0.4ml/min. 
High-throughput Aspirin hydrolytic activity assay by Reversed Phase High 
Performance Liquid Chromatography 
Acetaminophen was used as an internal standard (Figure 10), allowing 
calculations to analyze aspirin hydrolysis according to under curve area. The 
concentration of salicylic acid defined by 200
138.12
HPLCvalue l dilutionfactor
hours
µ× ×
×
was 
used to calculate hydrolyzed aspirin per hour. 
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Figure 10. Isolation of acetaminophen, aspirin, and salicylic acid. A mixture of 
acetaminophen, aspirin, and salicylic acid was separated by RP-HPLC. Elution time 
of acetaminophen was 1.2 min; elution time of aspirin was 2 min; elution time of 
salicylic acid was 2.6 min. 
  
2.2.3. 
This method uses butyrylthiocholine instead of butyrylcholine as a substrate of 
BChE, whose hydrolysis generates a thio-group the reduced to form a copper 
ferrocyanide colored precipitate. Briefly, 0.2 M maleic acid (180 ml, 4.18g/180ml) 
was adjusted to pH 6 before use and then 0.1 M sodium citrate (15 ml, 441mg/15ml) 
was added into the maleic acid buffer. Then 0.03 M CuSO4 (30 ml) was added with 5 
mM potassium ferricyanide (30 ml, 49.3875mg/30ml) (avoiding light and acid) before 
the final volume was ajusted to 300ml. Finally 2 mM butyrylthiocholine iodide (0.6 
mg/ml; 171mg in 285ml) was added. Gels 
BChE activity staining 
electrophoretically resolving proteins under 
native condition were incubated with staining solution under gentle shaking, allowing 
brown-red bands to develope (Li, Sedlacek et al. 2005) (Figure 11).  
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Figure 11. Reaction of BChE activity staining. Butyrylthiocholine was employed as 
a substrate of BChE. Product thiocholine further reacts with ferricyanide to produce 
ferrocyanide which reacts with copper ion to make red-brown color precipitation. 
 
2.2.4. 
This method uses the Ellman reaction (Figure 12) with butyrylthiocholine as a 
substrate of BChE. The yellow reaction product is quantified at 412nm using both 96 
well plate and 1.5ml cuvette format. A DTNB stock solution (10mM in 10×PBS, 
diluted 10 times before use) and 200mM butyrylthiocholine iodide were mixed just 
before use at a 100 to 1 ratio, respectively.  
BChE activity assay 
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Figure 12. Ellman reaction. Thiocholine produced from butyrylthiocholine reacts 
with 5, 5’-dithiobis(2-nitrobenzoate) to form a yellow compound which can be 
detected and quantified at 412nm. 
 
2.2.5. 
200ml blood was drawn from a normal individual following a protocol 
approved by the Cleveland Clinic Institutional Review Board. Blood in 50ml aliquots 
was added into EDTA containing centrifuge tubes (500µl of 0.25M EDTA) and 
centrifuged 20 minutes at 4℃ at 2,000×g. Plasma (9ml) was mixed with 4.5 g KBr 
and rocked for 15 minutes for complete dissolution before 27 ml saline solution was 
added to each of 8 ultracentrifuge tubes. The KBr plasma mixture was added into the 
bottom of each ultracentrifuge tube before the tubes were sealed using a Beckman hot 
seal apparatus. The sealed tubes were centrifuged at 50,000×g in Ti50 rotor at 4℃ for 
Isolation of HDL, LDL, and VLDL 
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3 hours. After centrifugation, fractionation was performed by using P-3 Pharmacia 
peristaltic pump connected to a Frac-100 and/or to Gilson fraction collector to collect 
aliquot of 1 ml per tube (Figure 13). The specific gravity of the fractions was 
measured. Fractions containing LDL are those having a density of less than 1.063 
g/ml, but more than 1.019 g/ml. 
 
Figure 13. HDL, LDL, and VLDL separation by gradient density 
ultracentrifugation. HDL, LDL, and VLDL were separated by gradient density 
ultracentrfugation and were fractionationed to 18 fractions from HDL to VLDL. 
 
2.2.6. 
Substrate and column prepariation: PAF (41.84µl) was taken from stock of 5 
mg/ml in methanol, 400 nmol unlabeled PAF. [3H]PAF (9µl, 10µCi/nmol) was mixed 
with the unlabeled PAF and dried. The mixed PAF was suspended in 4 ml of HEPES 
buffer and frozen as 500 µl aliquots. Octadecylsilica gel cartridges were washed with 
3 ml CHCl3: methanol (1:2, v/v), then 3 ml 95% ethanol and finally with 3 ml H2O.  
PAF-AH activity assay 
Assay: A mixture of 10µl enzyme source with 5µl 400mM DTT and 40µl of 
PAF substrate were incubated at 37℃ for 15 minutes. 10 M acetic acid (50µl) was 
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added to stop the reactions and 750µl of 0.1 M sodium acetate. The released acetate 
(Figure 14) was isolated by passing through pre-washed Baker octadecylsilica 
cartridges (1ml, J.T. Baker Chemical Co.) before collecting the effluent in a 
scintillation vial containing 15 ml of scintillation cocktail (EcoliteTM) for 
quantification by a β-scintillation counting. 
 
 
Figure 14. PAF-AH hydrolyzes the sn-2 acetyl group of PAF. Cleaved [3H] labeled 
acetate was detected by scintillation counting to monitor hydrolyzed PAF. 
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2.2.7. 
Samples were prepared using 2× loading dye containing 5% of β-
Mercaptoethanol before SDS-PAGE was performed to separate the proteins. These 
were then transferred onto PVDF membranes and then incubated with 5% nonfat milk 
for 1 hour. Diluted primary antibodies (1:200-1:1000 according to the manufactory’s 
instruction) were incubated with the membrane with rocking for 1 hour and followed 
by three TBS washes. Species specific secondary antibodies (HRP-conjugated, 
1:10,000) were used to ligate the primary antibodies. Enzymatic Chemiluminescence 
(ECL) reagents (GE healthcare) and x-film were used to visualize the 
phosphorescence. 
Western Blotting 
2.2.8. 
Absolute quantification of protein concentration or mass is a required and 
routine step to estimate protein recovery at different stages during purification of 
proteins, to measure specific activity of enzyme, and to prepare known amount of 
protein for biophysical, functional and analytical analyses. Absolute measurements of 
protein require calibrated sets of external standards containing known amounts of 
stereotypic proteins. However, when comparing the relative amounts of proteins 
among different samples, external standards are not needed. There are four methods 
that are commonly used to quantify proteins, which were used more or less in my 
project, because each of these methods has its advantages and limitations. They are 
absorption of UV light by side chains and / or peptide bonds of the protein; 
Protein quantification 
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chromogenic reactions involving complexes formed under alkaline conditions 
between the protein and cuprous ions (BCA); binding of a chromophore to the protein 
(Bradford); dot-blotting and staining.  
Advantages and disadvantages of each method are concluded as followed. UV 
method can be performed directly on the samples, but in affectedly strong 
interferences by nucleic acids, buffer salts, and detergents; BCA (bicinchoninic acid) 
is compatible with detergents and adaptable for microtiter plate assay (Redinbaugh 
and Turley 1986), but it is interfered with by reducing agents, chelators, and lipids 
(Wessel and Flugge 1984; Morton and Evans 1992); Coomassie dye binding method 
is compatible with reducing agents and adaptable for microtiter plate assay 
(Redinbaugh and Campbell 1985), but not compatible with detergents (Morton and 
Evans 1992). 
Proteins from plasma or erythrocyte lysates were dialyzed against 50mM Tris-
HCl buffer, pH 7.2 at a 100 fold volume at 4℃ overnight 3 times. Some 
measurements were performed without protein dialysis. Methods were chosen as 
stated using instructions of manufacturer. 
2.2.9. 
Platelet activation was measured indirectly by measuring aggregation optically 
in an aggregometer (CHRONO-LOG, model 700). Washed platelets (2×108) were 
stirred at 600 rpm at 37℃ before stimulation with 5mg/ml collagen. Slope and 
Platelet aggregation 
 
 
36 
 
percentage of aggregation were recorded by monitoring light transmission comparied 
to buffer control.  
2.2.10. 
The human embryonic kidney 293 cell line (HEK 293) from the American 
Type Culture Collection (ATCC) was grown in Dulbecco's Modified Eagle Medium 
(DMEM) (Cleveland Clinic Foundation Medium Core Facility) supplemented with 10% 
fetal calf serum (Hyclone), and penicillin (100U/mL) and streptomycin (100µg/mL) 
in a humidified CO2 (5%) atmosphere at 37℃. HEK 293 cells (1×105 cells/well) were 
plated in 6-well plates. After 24 hours the cells were transfected with DNA plasmids 
of human platelet-activating factor acetylhydrolase 1B with a CMV promoter using 
lipofectamineTM 2000 (Invitrogen, Carlsbad, CA) that followed the manufacturer's 
instructions. After 32 hours cells were collected and washed twice by 1× PBS buffer.  
Cell culture and Overexpression 
2.2.11. 
Cell Isolation: Human erythrocytes were isolated from freshly drawn human 
blood (400 ml) from healthy volunteers. The blood was collected in EDTA (25 mM) 
and centrifuged at 2,000× g for 20 min. The supernatant was discarded, and the blood 
cells were suspended in saline solution (600 ml) and centrifuged as above. Recovered 
erythrocytes were washed twice more to remove contaminating plasma. All 
chromatography was carried out at 4 °C. 
Protein purification 
DEAE chromatography: Erythrocytes (100 ml) were lysed hypotonicly by 100 
ml 0.2% NaCl. Membrane debris was isolated by ultracentrifugation at 10,000×g for 1 
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hour at 4°C. Supernatants (200 ml) of erythrocyte lysates were diluted by to 1L in 
50mM Tris-HCl (pH 7.4) containing 1 mM EDTA and loaded onto 500 ml DEAE 
SepharoseTM FF column. The column was conditioned with equilibrating buffer (50 
mM Tris-HCl pH 7.4) until virtually no protein eluted from the resin (1-1.5 liters of 
buffer). This step removed most of the hemoglobin, which is one of the major proteins 
in this preparation. The aspirin hydrolytic activity was eluted from the gel by 0-0.5 M 
linear gradient of sodium chloride in 50 mM Tris-HCl (pH 7.4). Fractions (8ml) were 
collected and assayed for protein content and aspirin hydrolytic activity. The major 
aspirin hydrolytic activity was detected in fraction 34 to fraction 44. These fractions 
were pooled and concentrated to 20 ml using Pierce® concentrators (Thermo 
scientific). The concentrated preparation (5 ml) was diluted to 100 ml with 50 mM 
Tris-HCl (pH 7.4) and passed through a second DEAE column (50 ml) and eluted 
with linear gradient sodium chloride solution (0-0.1M) buffered by 50 mM Tris-HCl 
(pH 7.4). Fractions (4 ml) were collected and assayed for protein content and aspirin 
hydrolytic activity. Most of the aspirin hydrolytic activity was again present in 
fraction 35 to fraction 43. Fractions with aspirin hydrolytic activity were pooled and 
concentrated to 5 ml using Pierce® concentrators (Thermo scientific).  
HiTrap Q chromatography: Concentrated preparations from DEAE 
chromatography (5 ml) were diluted to 60 ml and loaded onto a 5 ml HiTrap Q 
column conditioned by 50 mM Tris-HCl (pH 7.4) and eluted with a 0-0.1M linear 
gradient NaCl. Fractions (1 ml) were collected and measured for protein content and 
aspirin hydrolytic activity. The major aspirin hydrolytic activity was in fraction 40 to 
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fraction 50. After measuring activity, fractions with aspirin hydrolytic activity were 
pooled and concentrated to 1 ml using Pierce® concentrators (Thermo Scientific). 
Sephacryl S-200 chromatography: The pooled, concentrated fractions from 
the column HiTrap Q column were loaded on a Sephacryl S-200 column (1 × 60 cm) 
conditioned in 50 mM Tris-HCl buffer (pH 7.4) containing 150 mM NaCl. Collected 
fractions (1 ml) were assayed for protein content and aspirin hydrolytic activity before 
pooling and concentrating active fractions. 
2.2.12. 
Purified protein was further separated by SDS-PAGE. The bands were 
carefully cut from the Commassie stained gel with a special cleaned cutter and then 
destained in ethanol (50%) and acetic acid (5%). The destained bands were 
dehydrated in acetonitrile, dried in a Speed-vac, and digested with trypsin. Briefly, 5 
μL of 10 ng/μL trypsin is added in 50 mM ammonium bicarbonate and incubated with 
dried bands overnight at room temperature and followed by peptides extraction by 
adding two aliquots of 30 μL acetonitrile (50%) containing formic acid (5%) (Gandhi, 
Wang et al. 2008). The LC-MS used was a Finnigan LTQ linear ion trap mass 
spectrometer system. The HPLC column was a self-packed 9 cm × 75 μm id 
Phenomenex Jupiter C18 reversed-phase capillary column. 10μL of the extracted 
peptides mixture were injected onto the column and then was eluted by a mobile 
phase of acetonitrile/0.1% formic acid gradiently at a 0.25 μL/min flow rate, which 
was then introduced into the on-line mass spectrometer. The data were searched 
Mass spectrometry 
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against the NCBI non-redundant database via Mascot using a human taxonomy filter 
and verified by manual interpretation.  
2.2.13. Enzyme Kinetics
Aspirin concentrations were varied over a range of 0.25 mM to 8 mM with 
incubation for 1 hour at 37°C. Some experiments were incubated with aspirin in the 
presence of platelet-activating factor as an inhibitor. Experiments were triplicate and 
mean was used to further analysis. Data were fitted using the prism 4 software to 
obtain kinetic parameters. 
: 
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CHAPTER III 
3. CHARACTERIZATION AND IDENTIFICATION OF HUMAN PLASMA 
ASPIRIN HYDROLASES 
 
3.1. Introduction 
Aspirin, the first synthesized drug, is commonly used as an analgesic, anti-
pyretic, anti-inflammatory, and anti-platelet drug in the world and it is consumed over 
100 billion tablets each year (Warner and Mitchell 2002). Aspirin significantly 
reduces mortality and re-infarction in cardiovascular diseases (Awtry and Loscalzo 
2000; Baigent, Blackwell et al. 2009). It is wildly used as a prophylaxis reagent of 
cardiovascular and thrombotic diseases in a low dose (75-81mg/day) manner. This 
takes advantage of aspirin’s anti-platelet function, which first known in 1980s.  
Aspirin is a derivative of salicylic acid by acetylation and its pharmacological 
and molecular structure (Byrn and Siew 1981; Kim and Machida 1986) characters 
resemble those of salicylic acid. But the reactive acetyl group gives aspirin specific 
biological activities comparing to  salicylic acid through the nonselective acetylation 
of proteins and DNA (Pinckard, Hawkins et al. 1968). Studies have shown that a lot 
of proteins, nuclear acids, and lipids can be acetylated by aspirin in vivo and in vitro 
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(Thun, Namboodiri et al. 1991). The acetylation effect of aspirin has also been seen in 
albumin (Zandi and Breitner 2001), hemoglobin (Bridges, Schmidt et al. 1975), and 
erythrocyte membrane peptides (Fiorucci, de Lima et al. 2002), suggesting acetylation 
by aspirin should be nonspecific. However, the primary medical therapeutic target of 
aspirin in preventing CVD is showed as acetylation of Cyclooxygenase-1 in platelets 
and Cyclooxygenase-2 in other cells. The primary target of aspirin in platelets, 
Cyclooxygenase-1, is irreversibly inactivated by acetylation at its serine 530 residue 
(Smith, DeWitt et al. 1990) (Vane 1971). Cyclooxygenase-1 is continually 
synthesized in nucleated cells to substitute the inactive ones, but this will not happen 
in anucleate platelets. The ideally situation for anti-platelet effect of aspirin is that 
Cyclooxygenase-1 pathways are blocked specifically in platelets without touching 
that in other cells. Prostaglandin H2 metabolized from arachidonic acid by PLA2 in 
platelets is rapidly converted to the unstable endoperoxide thromboxane A2 (TxA2), 
that specifically stimulates the thromboxane A2 (TxA2) receptor of platelets 
(FitzGerald 1991). Activation of this receptor courses and enhances platelets response 
to stimuli by agonists including ADP and collagen, so if blocking this pathway 
platelet reactivity will be reduced. Thus, carefully choosing the right doses of aspirin 
is important to increase therapeutic effects and reduce side effects.  
Aspirin is transient with a half-life of 15-20 minutes in circulation, but its 
inhibition of cyclooxygenase is irreversible resulting in lifelong suppression of 
platelet thromboxane synthesis (Needs and Brooks 1985; Higgs, Salmon et al. 1987; 
Awtry and Loscalzo 2000). However, certain individuals, e.g. diabetics or stroke 
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survivors, may not receive the full protection from CVD by low dose aspirin 
administration, although defining, measuring and assessing aspirin resistance is 
complex and incomplete (Fitzgerald and Maree 2007; Patrono and Rocca 2007; Lev 
2009; Santilli, Rocca et al. 2009; Pignone and Williams 2010). As I discussed above, 
acetyl group is the key for aspirin in suppressing platelet function. Hydrolysis of its 
acetyl group will destroy its anti-platelet ability. However, aspirin hydrolysis in serum 
is not normally distributed (Adebayo, Williams et al. 2007) and is increased in 
patients with type 2 diabetes (Gresner, Dolnik et al. 2006; Kotani, Kimura et al. 2010), 
atherosclerosis (Akopov, Grigorian et al. 1992), aspirin-sensitive asthma or cold 
uticaria (Williams, Asad et al. 1987), or after surgery (Puche, Gomez-Valverde et al. 
1993). Since aspirin hydrolysis in vivo is an enzymatic event, looking for responsible 
enzymes for aspirin hydrolysis will be a worthwhile way to unveil the complex. 
The identity of the enzyme(s) in plasma that hydrolyzes aspirin remains 
unknown despite its wide use and hundred years’ history. The effects of turnover on 
its efficacy are important, which is directly controlled by aspirin hydrolases. Aspirin 
hydrolase activity and butyrylcholinesterase (BChE) activity in plasma are correlated 
positively and their distributions are skewed (Adebayo, Williams et al. 2007). 
However, BChE hydrolyzes aspirin, which is different from its way of hydrolyzing 
butyrylcholine esters (La Du 1971). The other aspirin hydrolytic activity in plasma is 
still undefined, although it is believed to be albumin (O'Brien 1968). Aspirin 
hydrolytic activity has been found in cells where enzymes were shown to include 
uridine diphosphate glucuronyl transferase (Bigler, Whitton et al. 2001; Chan, Tranah 
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et al. 2005) and carboxylesterase 2 (Mentlein and Heymann 1984; Yamaori, Fujiyama 
et al. 2006). Thus, aspirin hydrolysis is not a behavior of a single enzyme that 
hydrolyzes aspirin.  
Because aspirin has acetylation effects, which is a nonspecific process, 
assessing aspirin hydrolysis becomes complicated. For example, loss of [3H]acetate 
from [3H]aspirin includes non-enzymatic derivitization of accepters such as albumin 
(Yang, Bian et al. 2007; Lockridge, Xue et al. 2008) and water. There are esterases 
with broad spectrum substrate specificity, so-called non-specific esterases, which 
catalyze aspirin hydrolysis. These might be the reason enzymes responsible for aspirin 
hydrolysis is still undefined. However, aspirin is an artificial compound and its 
hydrolysis by enzymes is not an evolutionarily selected trait, and so reflects the action 
of one or more esterases that happen to accept it as a substrate. Fortunately, there are 
studies which have been found enzymes as aspirin hydrolases, but still far way to go 
to elucidate aspirin resistance. Esterases hydrolyzing aspirin include 
butyrylcholinestease, abundantly existing in plasma  (Masson, Froment et al. 1998) 
(Adebayo, Williams et al. 2007). Most recently paraoxonase-1 (PON1) has been 
shown to hydrolyze aspirin and aspirin nitrate, a novel anti-inflammatory agent 
(Santanam and Parthasarathy 2007). 
The physiologic function of plasma butyrylcholinesterase is not well defined. 
Its hydrolysis of organophosphates is of potential benefit after exposure to 
organophosphate based nerve agents (Saxena, Sun et al. 2011), and it hydrolyzes 
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acetylated drugs and choline-containing local anesthetics (Goodall 2004). The 
genotype and phenotype of butyrylcholinesterase are convoluted, which leading to the 
kinetics of the tetramer (Goodall 2004) are complex (Simeon-Rudolf, Reiner et al. 
1999). It has several identified isomers and mutations, which makes understanding 
physiological role of BChE more difficult. People tried to distinguish these variations 
base on the dibucain number that reflects catalysis and clearance of local anesthetics 
(Goodall 2004). Butyrylcholinesterase hydrolyzes aspirin (Masson, Froment et al. 
1998), but its actual contribution to aspirin hydrolysis in plasma remains undefined.  
I directly assessed aspirin hydrolysis in human plasmas by isolating and 
quantifying the salicylic acid produced from aspirin by RP-HPLC to find aspirin 
hydrolysis in plasma among people is complicated, and highly variable. PON1 was 
found to not hydrolyze aspirin. Butyrylcholinesterase hydrolyzes aspirin, but BChE 
null plasma still hydrolyzed aspirin normally. I found significant variation exists in 
batch total plasma aspirinase activity and the variation of plasma aspirin hydrolytic 
activity is genetically encoded. Genome wide association analysis effectively 
correlated gene of butyrylcholinesterase with this variation, although genetic deletion 
was not informative. However, a non-BChE aspirinase activity with little variation 
exists in plasma that I show to conduct with type I PAF acetylhydrolase. 
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3.2.  Results  
3.2.1.  Plasma hydrolyzes aspirin enzymatically. 
Structurally, aspirin should have had the most same pharmacological 
properties as salicylic acid. However, after the acetyl modification, aspirin gains new 
functions, anti-platelet function, and promote generation of biologically active 
Lipoxins (Brezinski, Nesto et al. 1992). After incubation with plasma at 37℃ for 2 
hours, aspirin was found mostly hydrolyzed to salicylic acid (Figure 15). This is an 
enzymatically behavior. When I heated plasma at 75 ℃ for 2 hours, it totally lost its 
ability to hydrolyze aspirin (Figure 16). I also determined the effect of time on aspirin 
hydrolysis by plasma, and found it was linear (Figure 17). Since aspirin hydrolysis in 
plasma is an enzymatical behavior, I also examined effect of EDTA, an anti- 
agglutination agent, on aspirin hydrolysis. No effect of EDTA was found on aspirin 
hydrolysis by plasma (Figure 18). 
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Figure 15. Human plasma hydrolyzes aspirin efficiently in 2 hours. Aspirin 
(10μg) was incubated with 100μl 1mM EDTA treated human plasma at 37℃ for 2 
hours. The reaction was stopped by adding 1% formic acid, and aspirin and salicylic 
acid were extracted by ethyl acetate: diethyl ether (4:1, v/v). The organic phase was 
separated and dried under N2. Recovered aspirin and salicylic acid were reconstituted 
in 500 μl of HPLC solvent (1% glacial acetic acid: methanol, 60:40, v/v) and 50 μl 
was analyzed by RP-HPLC.  
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Figure 16．Heated human plasma does not hydrolyse aspirin. EDTA (1 mM) 
treated human plasma was heated at 75 ℃ for 2 hours. And then 100 μl heated plasma 
was incubated with 10 μg aspirin at 37℃ for 2 hours. The reaction was stopped by 
adding 1% formic acid, aspirin and salicylic acid were extracted by ethyl acetate: 
diethyl ether (4:1, v/v). The organic phase recovered was dried under N2. Aspirin and 
salicylic acid were then reconstituted in 500 μl of HPLC solvent (1% glacial acetic 
acid: methanol, 60:40, v/v) and 50 μl was analyzed by RP-HPLC.  
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Figure 17．Time course of Aspirin hydrolysis. Aspirin (50 μg) in 500 μl PBS was 
incubated with 500 μl human plasma and at each time point (0, 30, 60, 120min) 200μl 
mixture was removed before the reaction was stopped by adding 1% formic acid and 
aspirin and salicylic acid were extracted by ethyl acetate: diethyl ether (4:1, v/v). The 
organic phase was separated and dried under N2, aspirin and salicylic acid were 
reconstituted in 500 μl of HPLC solvent (1% glacial acetic acid: methanol, 60:40, v/v) 
and 50 μl was analyzed by RP-HPLC. Data are presented as Mean ± S.D., n>3.  
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Figure 18．EDTA does not inhibit aspirin hydrolysis by human plasma. Human 
plasma was treated with 2mM EDTA, which totally inactivates PON-1 activity (data 
not shown). This plasma (100μl) was incubated with 10 μg aspirin at 37℃ for 2 hours 
before reaction was stopped by adding 1% formic acid. Aspirin and salicylic acid 
were extracted by ethyl acetate: diethyl ether (4:1, v/v). The organic phase was 
separated and dried down under N2. Recovered aspirin and salicylic acid in 500 μl of 
HPLC solvent (1% glacial acetic acid: methanol, 60:40, v/v) was analyzed by RP-
HPLC.  
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3.2.2. PON1 is not an aspirin hydrolase 
PON1 is a Ca2+ dependent enzyme and has been shown to hydrolyze aspirin 
(Santanam and Parthasarathy 2007). However, I found EDTA anti-agglutinatied 
plasma had intact aspirin hydrolytic activity, suggesting PON1 lacks aspirin 
hydrolytic activity. PON1 is an HDL associated protein, as I first isolated HDL and 
LDL from acid citrate dextrose (ACD) anti-agglutinatied plasma by KBr gradient 
density centrifugation and collected it into 18 fractions from bottom to top. Both 
aspirin hydrolytic activity and aryl esterase activity were examined in each fraction 
(Figure 19). Aspirin hydrolytic activity did not co-localize with aryl esterase activity. 
Aspirin hydrolytic activity was found in fraction 1 and 2 (soluble material), but aryl 
esterase activity or PON activity was found in fraction 4 to 6. Western blotting for 
PON1 and Apo A-I, an HDL protein, were perform to further confirm the location of 
PON1. I also examined recombinant PON1 for aspirin hydrolytic activity. Active 
recombinant PON1 did not hydrolyze aspirin at 2.5μg, which had 2 times more aryl 
esterase activity than that of 10μl plasma (Figure 20). Over all, PON1 cannot be an 
aspirin hydrolase, nor is any other lipoprotein-associated enzymes. 
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Figure 19．Aspirin hydrolytic activity does not co-localize with aryl esterase 
activity. Human plasma was subjected to density gradient (KBr) centrifugation. 20 
fractions were collected (from HDL to VLDL). Each fraction is tested for aspirin 
hydrolysis and PA hydrolysis (aspirin hydrolytic activity and PON1 activity). A 
portion of each fraction was taken and was separated by SDS-gel electrophoresis. 
Western Immunoblotting was performed for PON-1 and Apo A-I.  
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Figure 20. Recombinant PON1 does not hydrolyze aspirin. Recombinant PON1 
does not hydrolyze aspirin. Arylesterase and aspirin hydrolytic activity of plasma and 
recombinant PON1 (2.5µg) were determined as above. Data are presented as mean ± 
S.D., n=3. 
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3.2.3. Plasma platelet-activating factor acetylhydrolase shows weak aspirin 
hydrolytic activity. 
Platelet-activating factor acetylhydrolase (PAFAH) hydrolyzes the acetyl 
group at the Sn-2 position of platelet-activating factor (PAF, 1-O-alkyl-2-acetyl-sn-
glycero-3-phosphocholine), which inactived it. I examined if PAFAH accounted for 
plasma aspirin hydrolytic activity. PAFAH activity was measured in 18 plasma 
density gradient centrifugation fractions (Figure 21A). I found that 2/3 of the PAFAH 
activity was in LDL and 1/3 of the PAFAH activity was in HDL corresponding to the 
expected physical distribution, which did not collocate with aspirin hydrolytic activity 
(Figure 19). I calculated amount of plasma PAFAH in the lipoprotein fraction, which 
was about 0.05μg. I used the same amount of recombinant plasma PAFAH (0.05μg) 
to measure aspirin hydrolytic activity, but could not detect activity. However, 2μg 
recombinant plasma PAFAH did display detectable aspirin hydrolytic activity (Figure 
21B). This suggests that aspirin is a poor substrate of plasma PAFAH. 
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Figure 21. Abundance of plasma Platelet activating factor – acetylhydrolase 
(PAF-AH) in LDL. Human plasma was subjected to density gradient (KBr) 
centrifugation as before. 20 fractions were collected (from HDL to VLDL). A portion 
of each fraction was taken and incubated with [3H-acetyl]PAF at 37℃ for 15 min. 
Hydrolyzed 3H acetate was separated and collected on a C18 column. PAF-AH 
activity was calculated by converting the counts of [3H]acetic acid produced by 
hydrolyzed [3H-acetyl]PAF. (A). A portion of each fraction was separated by SDS-
PAGE and western immunoblotting was performed for plasma PAF-AH (B). LDL 
fractions do not hydrolyse aspirin. Data are presented by mean ± S.D., n>3. 
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3.2.4. Butyrylcholinesterase cannot account for all of the plasma aspirin hydrolytic 
activity. 
I examined Butyrylcholinesterase (BChE) for aspirin hydrolytic activity. 
Purified plasma BChE hydrolyzed aspirin efficiently, which was inhibited by eserine, 
a selective inhibitor of BChE (Figure 22). However, BChE and total plasma aspirin 
hydrolytic activity were not congruous with each other. I measured both aspirin 
hydrolytic activity and BChE activity which used butyrylthiocholine as a substrate 
(Figure 23). Ratios of plasma aspirin hydrolytic activity to BChE activity were not 
consistent in 14 donors. This suggests that BChE is not the only plasma aspirin 
hydrolase.  
I purified plasma aspirin hydrolytic activity and examined amount of BChE in 
purified plasma aspirin hydrolase by comparing with BChE standard (Figure 24A). I 
found BChE only contributes in part to plasma aspirin hydrolysis. Fraction 1 (800 μg 
protein), where all the aspirinase activity of plasma existed, has an aspirinase activity 
more than 200ng BChE has. But western blotting only detected about 50 ng BChE in 
Fraction 1 (800 μg). For confirmation, I examined BChE null plasma, which totally 
lacks Butyrylthiocholine hydrolytic activity because of a silent mutation, for aspirin 
hydrolysis (Figure 24B). Surprisingly, I found normal plasma aspirin hydrolytic 
activity in the BChE null plasma. Albumin was therefore examined for aspirin 
hydrolytic activity as a potential catalyst since it deacelates aspirin (Liyasova, 
Schopfer et al. 2010). I examined location of albumin and ability of aspirin hydrolysis 
(Figure 25). The location of albumin in density gradient centrifugation fractions did 
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not localize with aspirin hydrolytic activity, although a tiny amount aspirin hydrolysis 
was detected in the albumin rich fractions (Burch and Blazer-Yost 1981). 
 
 
 
 
 
 
Figure 22. BChE hydrolyzes aspirin. 200 ng purified plasma BChE was incubated 
with 4 mM aspirin at 37℃ for 2 hours in the presence or absence of eserine. Salicylic 
acid product was quantified by RP-HPLC. Data are present as mean ± S.D., n=3. 
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Figure 23. Aspirin hydrolytic activity and BChE activity in plasma of 14 donors. 
(A) Aspirin hydrolytic activity was measured in 14 donors’ plasma. (B) BChE activity 
was measured in 14 donors’ plasma. (C) The ratio of the two activities was calculated 
by mean (C). Data are presented as mean ± S.D., n=3. 
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Figure 24．Butyrylcholineseterase appears to contribute little to plasma aspirin 
hydrolysis. (A) Plasma butyrylcholinesterase is a minor contributor to aspirin 
hydrolysis. Plasma was separated by density gradient centrifugation and fraction 1 
containing aspirin hydrolytic activity was partially purified by Cibacron® blue 
chromatography. Butyrylcholinesterase protein in this fraction was assessed by 
western blotting (top) or aspirin hydrolytic activity (bottom) quantified by HPLC in 
comparison to known quantities of butyrylcholinesterase purified from human plasma. 
(B) Butyrylcholinesterase and aspirin hydrolytic activity were determined in normal 
human plasma and plasma from an individual with an inactivating null mutation in 
butyrylcholinesterase. Data are presented as mean ± S.D., n=3. 
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Figure 25. Nondenaturing gel stained for BChE activity with butyrylthiocholine. 
(A) 10 μl of each fraction (KBr gradient) is separated by a 10% native polyacrylamide 
gel. Fraction 1, 2 and 3 were shown BChE tetramers, trimers, dimers, and monomers. 
Staining procedure is described in Method part. (B) Albumin western blotting of each 
fraction. (C) Aspirin hydrolysis in plasma and albumin. Normal, BChE null plasma, 
and albumin (adjusted to physiological concentration, 0.5%) (10 µl) are incubated 
with 4 mM aspirin at 37°C for 2 hours, and then quantitate aspirin hydrolysis. Data 
are present as mean ± S.D., n=3. 
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3.2.5. Composition of plasma aspirin hydrolytic activity 
I measured both butyrylthiocholine hydrolytic activity (BTC activity) and 
aspirin hydrolytic activity of BChE and BChE null plasma to assess non-BChE 
plasma aspirin hydrolase activity. The ratio of BTC activity to aspirin hydrolytic 
activity shows the two activities are distinctive (Table 1). For BChE, the ratio is 21.81; 
for BChE null plasma, the ratio is 0.35. These data can be used to estimate the relative 
contribution of the two aspirinase in plasma to total aspirin hydrolysis, using these 
ratios to define overlap in activities. If I set the percentage of plasma aspirin 
hydrolytic activity coursed by BChE as x and that by non-BChE aspirin hydrolase as 
y, I obtain Equation 1, where z stands for real ratio of BTC activity to aspirin 
hydrolytic activity in plasma. I measured the ratio of BTC activity to aspirin 
hydrolytic activity in 14 donor’s plasma and calculated the percentage composition of 
plasma aspirin hydrolytic activity (Figure 26). This shows that the theoretical 
compositions of BChE and non-BChE aspirin hydrolases are about equaul. 
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Table 1 
   BChE  BChE null  plasma 
BTC activity 
(U/ml/min)  
  
78.07  1.49  
Aspirin hydrolytic activity  
(nmol/ml/min)  
 
3.58  4.28  
Ratio 
(BTC/Aspirin hydrolytic activity)  21.81  0.35  
n=3; data presented by Mean; 1U=265.2nmoles 
 
 
 
 
 
 
Equation 1 
1
21.81 0.35
x y
x y z
+ =
+ =  
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Figure 26. Theoretical composition of plasma aspirin hydrolytic activity. 
According to the formula, composition of plasma aspirin hydrolytic activity was 
calculated. 
 
 
3.2.6. Butyrylcholinesterase accounts for variation of plasma aspirin hydrolytic 
activity 
The above approach calculated the composition of plasma aspirin hydrolytic 
activity and suggested the conclusion that two enzymes at least in plasma hydrolyze 
aspirin. I found significant variation among individuals and then used inhibitors to 
show the contribution of the two enzymes in those donors. First I investigated plasma 
aspirin hydrolytic activity in 7 donors, and found significant variation (Figure 27A).  
The maximum of plasma aspirin hydrolytic activity was about 1482 nmol/ml/hour and 
the minimum of plasma aspirin hydrolytic activity was about 220 nmol/ml/hour with a 
mean of about 500 nmol/ml/hour. Oxidized ATP was found to inhibit aspirin 
hydrolytic activity in BChE null plasma, and inhibited little that of pure BChE, so it 
can be used to assess non-BChE activity. Conversely, procainamide inhibited aspirin 
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hydrolytic activity of BChE, and accordingly had little effect in null plasma (Figure 
27B). Oxidized ATP effectively inhibited recombinant PAFAH1b2. I used these two 
inhibitors to elucidate the actual composition of plasma aspirin hydrolytic activity 
(Figure 27C). I found BChE accounts for the variation of plasma aspirin hydrolytic 
activity, and that non-BChE aspirin hydrolase activity was fairly constant. Tris buffer, 
an activity enhancer of BChE, significantly increases aspirin hydrolysis by plasma, 
but did change the variation trends in the 7 donors (Figure 28). These suggest that 
BChE contributes the variation of aspirin hydrolytic activity in the donors.  
I then examined aspirin hydrolytic activity in 2,275 serum samples to 
determine if the variation was genetically encoded and if so, if both BChE and non-
BChE enzyme were responsible. Again I found significant variation in this large 
population. The highest activity was about 37 nmol/ml/min and the lowest activity 
was about 3 nmol/ml/min. The difference was up to 12-fold (Figure 29A). Genome-
wide association analysis was performed to map serum aspirin hydrolytic activity to 
the entire genome. BChE is the only gene related to serum aspirin hydrolytic activity 
variation (Figure 29B). The p value is 6.4×10-14. All together, BChE contributes 
variation of plasma aspirin hydrolytic activity and this is genetically encoded. 
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Figure 27. Aspirin hydrolysis in plasma is variable, with variable contribution by 
butyrylcholinesterase. (A) Box and whisker plot of plasma aspirin hydrolytic 
activity. Aspirin hydrolysis by plasma of seven donors is depicted with maximum 
(1482 nmol/ml/h), minimum (220 nmol/ml/h), lowest and highest quartile and the 
median. (B) Both butyrylcholinesterase and at least one other activity contribute to 
aspirin hydrolysis in normal human plasma. Aspirin hydrolytic activity in normal 
plasma, BChE null plasma, and recombinant PAFAH1B2 were examined in the 
presence of procainaminde to inhibit butyrylcholinestersase and oxidized ATP to 
inhibit non-butyrylcholinesterase activity. (C) Plasma aspirin hydrolytic activities 
vary among donors, but largely from difference among BChE activity. Aspirin 
hydrolysis in plasma from distinct donors in the presence of procainamide or oxidized 
ATP was quantified as above. Data are presented as mean ± S.D., n=3. 
 
 
 
 
65 
 
 
 
 
 
 
 
1 2 3 4 5 6 7
0
1000
2000
3000
4000
PBS buffer
Tris buffer
Donor
As
pi
rin
 h
yd
ro
ly
tic
 a
ct
iv
ity
(n
m
ol
/m
l/h
ou
r)
 
Figure 28. Tris buffer enhances aspirin hydrolysis by plasma. 4 mM aspirin was 
incubated with 10 μl plasma in PBS buffer or Tris buffer at pH 7.4 at 37℃ for 2 hours. 
Aspirin hydrolyzed was quantified by RP-HPLC. 
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Figure 29. Variation in serum aspirin hydrolytic activity is widespread, and 
genetic variation primarily correlates to butyrylcholinestease. (A) High 
throughput HPLC analysis of aspirin hydrolysis in 2,275 serum samples. Analysis 
used a single measurement, which was validated by randomly re-analysis of 285 
samples. (B) Manhattan plot of genome-wide p values for association with serum 
aspirin hydrolytic activity. 
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3.2.7. Type I PAFAH accounts for non-BChE plasma aspirin hydrolytic activity. 
I identified type I PAFAH as erythrocyte aspirin hydrolase (Chapter IV). 
When I identified bands responsible for erythrocyte aspirin hydrolytic activity, one of 
the candidates is ATPase. So ATP was used as an inhibitor and aspirin hydrolytic 
activity of type I PAFAH was inhibited by ATP (Figure 30). I used oxidized ATP as 
an inhibitor for erythrocyte aspirin hydrolase, which is more stable than ATP. It also 
inhibited type I PAFAH as ATP. I also examined effects of oxidized ATP and 
procainamide on aspirin hydrolytic activity of type I PAFAH. The same as non-BChE 
plasma aspirin hydrolase, type I PAFAH also inhibited by oxidized ATP, but not 
inhibited by procainamide (Figure 31). This made me think the possibility that type I 
PAFAH may account for non-BChE plasma aspirin hydrolytic activity. I did western 
blotting for PAFAH1B2 in density gradient centrifugation fractions, which I knew 
aspirin hydrolytic activity was in fraction 1. PAFAH1B2 was detected in fraction 1 
where most aspirin hydrolytic activity existed (Figure 32). To confirm, western 
blotting for PAFAH1B2 was also performed in BChE null plasma along with 7 other 
plasmas. PAFAH1B2 was found in all plasmas, especially in BChE null plasma. 
Another phenomenon was that serum had more aspirin hydrolytic activity than plasma 
from same donor (Figure 33). These suggest aspirin hydrolytic activity of BChE null 
plasma is from type I PAFAH and type I PAFAH accounts for parts of plasma aspirin 
hydrolytic activity. 
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Figure 30. PAFAH1B is inhibited by ATP and oxidized ATP. 4 mM aspirin was 
incubated with purified type I PAFAH at 37°C for 2 hours in the presence or absence 
of ATP or oxidized ATP and followed by measurement of aspirin hydrolytic activity. 
Data are normalized to control and presented by mean ± S.D., n≥3. 
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Figure 31. Both PAFAH1B and BChE null plasma were inhibited by oxidized 
ATP, but little inhibited by procainamide. Purified erythrocyte aspirin hydrolase 
was incubated with 4 mM aspirin in the presence or absence of inhibitors (2 mM 
oxidized ATP and 20 mM procainamide) at 37°C for 2 hours. Hydrolyzed aspirin was 
measured by RP-HPLC. Data are presented by mean ± S.D., n≥3. 
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Figure 32. Type 1 PAFAH accounts for aspirin hydrolytic activity of BChE null 
plasma. Aspirin hydrolytic activity was measured in plasma density gradient 
centrifugation fractions. Each fraction was immunoblotted by PAFAH1B2 with 
erythrocyte lysate as a positive control. Only fraction 1 was detected PAFAH1B2. 
Immunoblot for PAFAH1B2 was performed in BChE null plasma along with seven 
different normal plasmas. PAFAH1B2 was detected in all plasmas. Data are presented 
by mean ± S.D., n≥3. 
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Figure 33. Comparison of time course aspirin hydrolysis by serum and plasma. 4 
mM aspirin was incubated with 1ml of serum or plasma at 37°C. 50 μl was taken out 
at each time point and followed quantification of salicylic acid by RP-HPLC. Data are 
presented by mean ± S.D., n≥3. 
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3.3. Discussion 
Aspirin is used worldwide medically to prevent cardiovascular and thrombotic 
diseases. However, not all individuals or members of groups appear to receive the 
benefits of aspirin administration. In recent decades more cases of aspirin treatment 
failure drew people’s attention, which was commonly termed “aspirin resistance”, but 
whether the phenomenon of “aspirin resistance” is a valid description, or even 
identifiable given difficulties in clinical measurement of platelet function (Santilli, 
Rocca et al. 2009), is debated (Fitzgerald and Maree 2007; Patrono and Rocca 2007).  
Clinical studies showed that aspirin resistance in population is about 8-45% 
(Grotemeyer 1991; Grotemeyer, Scharafinski et al. 1993; Helgason, Tortorice et al. 
1993; Gum, Kottke-Marchant et al. 2001). The wide range of percentage of aspirin 
resistance observed is because of methods used to identify it. Resistance to aspirin can 
be identified in ex vivo assays of platelet reactivity, in in vivo studies (Fitzgerald and 
Maree 2007), or the apparent lack of efficacy in defined populations (Fitzgerald and 
Maree 2007; Patrono and Rocca 2007; Lev 2009; Santilli, Rocca et al. 2009; Pignone 
and Williams 2010). A molecular basis for insensitivity to aspirin could include 
events that depend on thromboxane A2 signaling pathways, but also would include 
aspirin bioavailability as observed in populations associated with aspirin insensitivity 
(Williams, Asad et al. 1987; Akopov, Grigorian et al. 1992; Puche, Gomez-Valverde 
et al. 1993; Gresner, Dolnik et al. 2006). 
 Although aspirin has been in massive use since its introduction in the 1890s, 
its metabolism in blood remains undefined. Aspirin is not a physiologic metabolite 
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whose metabolism was subject to selection, so its hydrolysis reflects activity of 
esterases that can accept it as a substrate. However, the key enzymes responsible for 
the process of metabolism are still unknown. Aspirin acetylates albumin (Yang, Bian 
et al. 2007) that reversibly binds and transports the drug (Costello and Green 1987), 
and circulating esterases paraoxonase-1(Santanam and Parthasarathy 2007) and 
butyrylcholinesterase (Masson, Froment et al. 1998) are able to accept aspirin as a 
substrate and hydrolyze this simple salicylate ester.  
I detected about 20% of aspirin hydrolytic activity in purified human serum 
albumin comparing with normal plasma containing same amount of albumin, but it 
still cannot account for the aspirin hydrolytic activity in BChE null plasma. Location 
of albumin in gradient density centrifugation fractions (1-6) was distinct from the 
location of aspirin hydrolytic activity (fraction 1) which co-located with BChE. 
Albumin was reported having esterase activity (Morikawa, Inoue et al. 1979; 
Rainsford, Ford et al. 1980), but this was thought as “psuedoesterase activity” due to 
non-catalytic acetylation (Lockridge, Xue et al. 2008). So albumin actually cannot be 
an enzyme which responsible for plasma aspirin hydrolytic activity.  
Butyrylcholinesterase circulates as a tetramer that displays complex kinetics 
(Simeon-Rudolf, Reiner et al. 1999) subject to both environmental and genetic 
variation that obfuscates catalysis (Goodall 2004). Plasma aspirin hydrolytic activity 
is not normally distributed (Adebayo, Williams et al. 2007) and genetic variation 
affects butyrylcholinesterase activity that correlates with distinct neuromuscular 
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blockade in response to the anesthetic succinlycholine (Levano, Ginz et al. 2005), a 
butyrylcholinesterase substrate. Variation in plasma aspirin esterase activity 
additionally correlates with measures of type 2 diabetes (Gresner, Dolnik et al. 2006; 
Kotani, Kimura et al. 2010) that may be relevant to aspirin sensitivity. 
 I sought to identify the activity (ies) in plasma that hydrolyzed aspirin, rather 
than testing candidate enzymes for aspirin hydrolytic activity, by quantifying the 
salicylic acid product, unlike the acetyl group, that is not sequestered into non-
enzymatic adducts. PON-1 was shown having aspirin hydrolytic activity (Santanam 
and Parthasarathy 2007), but my data did not support it. Density gradient separation 
shows the plasma aspirin hydrolytic activity is soluble, and therefore cannot result 
from the lipoprotein associated esterase paraoxonase-1 even though this activity is 
suggested as plasma aspirin hydrolase (Santanam and Parthasarathy 2007). As we 
know PON-1 binds to Cibacron blue, but Cibacron blue binding proteins were not 
detected any aspirin hydrolytic activity (not shown). Finally, functionally recombinant 
PON-1 failed to hydrolyze aspirin. However, aspirin use was reported associated with 
higher serum concentration of PON-1 (Blatter-Garin, Kalix et al. 2003), which was 
believed because aspirin induced PON-1 expression (Jaichander, Selvarajan et al. 
2008). 
 I sought to define the role of circulating butyrylcholinesterase on aspirin 
metabolism by assessing aspirin hydrolysis in plasma obtained from an individual 
with a functional knockout as a consequence of a single, defined mutation (Nogueira, 
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McGuire et al. 1990). BChE null plasma still can hydrolyze aspirin efficiently, 
strongly indicating that BChE was not the only aspirin hydrolytic enzyme accounting 
for plasma or serum aspirin hydrolytic activity. Results from this classic approach 
would, and initially did, exclude this enzyme from consideration. Plasma deficient in 
this single enzyme, however, did reduce the complexity of aspirin hydrolysis, and 
complete inhibition of aspirin hydrolytic activity in this BChE deficient individual’s 
plasma by oxidized ATP was consistent with the presence of a single hydrolytic 
enzyme. Inhibition by oxidized ATP showed aspirin hydrolysis by this activity varied, 
up to two fold, among donors. Conversely, the butyrylcholinesterase inhibitor 
procainamide showed it too inhibited plasma aspirin hydrolytic activity, and that the 
effectiveness of this inhibition also varied among donors. Together the data suggests 
butyrylcholinesterase does participate in aspirin hydrolysis in plasma along with a 
currently unidentified esterase. The two plasma aspirin hydrolytic activities vary 
independently. Six-fold difference of aspirinase activity was observed coursing by 
BChE among donors, but little variation was observed in the unidentified esterase. 
With the identity uninformed of the non-BChE plasma aspirin hydrolase (BChE null 
plasma), I was still able to characterize the composition of them in plasma by their 
different substrates. BChE can hydrolyze both butyrylcholine and aspirin, but non-
BChE aspirin hydrolase can only hydrolyze aspirin. I measured both two activities 
(aspirin and butyrylcholine) and calculated the ratio of the two (Table 1). By using the 
two ratios, I proposed a formula and calculated theoretically percentage composition 
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of the two portions of activities. Results suggest that it is about half to half, which is 
consistent with the results of inhibition studies. 
 I determined if a component to the variation of aspirin hydrolysis was genetic 
through a genome-wide association study (GWAS). When I expanded the number of 
individual plasmas examined to 2,275, I discovered strong variation, up to 12-fold, in 
plasma aspirin hydrolysis. Adebayo GI et al. found 7-fold difference of serum aspirin 
hydrolytic activity in 107 individuals (Adebayo, Williams et al. 2007). Smaller 
samples studied may be the reason of lower difference observed. The activity range 
Adebayo GI et al. reported was 33.90 nmol/ml/min to 222.65 nmol/ml/min, which is 
higher than what I found (3.062 nmol/ml/min to 37.38 nmol/ml/min). The reason of 
the difference may because of different assay buffer used. 50 mM Tris (pH 7.2) buffer 
can increase plasma aspirin hydrolytic activity up to 6 fold comparing with that of 
PBS buffer at the same pH used. It has been shown as a character of normal BChE but 
not atypical BChE (La Du 1971). I also determined that this strongly associated with a 
single SNP located at the end of chromosome 3, so a single locus accounted for all of 
the significant variation in activity. Plasma aspirin hydrolysis is therefore genetically 
determined, and the SNP shows this locus is that encoding butyrylcholinesterase. 
GWAS has therefore identified this gene where biochemical and knockout strategies 
were ineffective.    
Characterization of non-BChE aspirin hydrolase by inhibitors reveals that the 
undetermined plasma aspirin hydrolase can be inhibited by oxidized ATP, but not by 
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procainamide, a selected inhibitor of BChE. I found recombinant PAFAH1b2 was 
inhibited by oxidized ATP and it was detected by Western Blot in BChE null plasma 
and normal plasma as well. These suggest that PAFAH1B accounts for the non-BChE 
plasma aspirin hydrolytic activity, which contributes about half of plasma aspirin 
hydrolytic activity. By inhibition studies, this activity has low variation among donors, 
which may be the reason that GWAS failed to detect it. 
My findings reveal that significant variation of serum aspirin hydrolytic 
activity exists among people, resulting from genetic BChE variation, in addition to 
varied amount of two aspirin hydrolases. The non-BChE aspirin hydrolytic activity is 
because of type I PAF acetylhydrolase. This may provide molecular basis for 
explanations of aspirin “resistance” and a starting point for personalized medicine of 
aspirin.  
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CHAPTER IV 
4. IDENTIFICATION AND CHARACTORIZATION OF ASPIRIN 
HYDROLASE IN HUMAN ERYTHROCYTES 
 
4.1. Introduction 
Since the anti-platelet function of aspirin primarily because of its acetyl group, 
it is important to know the pathways of losing acetyl group in blood. Aspirin 
acetylates cyclooxgenase-1 to suppress platelet activation, which most likely is 
controlled by rate of its hydrolysis. After first pass metabolism, about 70% of aspirin 
reaches blood and rapidly is hydrolyzed to salicylate enzymatically (Seymour, 
Williams et al. 1984). Therefore aspirin has a very short half-life (15-20min) in 
human circulation (Levy 1965; Rowland, Riegelman et al. 1972). Enzymes catalyzing 
aspirin hydrolysis play important roles in controlling lifespan of aspirin in blood and 
further negatively affecting its anti-platelet function. Plasma butyrylcholinesterase is a 
major aspirin hydrolytic activity (Rainsford, Ford et al. 1980) in blood. I have shown 
that a significant variation of plasma aspirin hydrolytic activity existed in population, 
which is up to 12-fold. And I also showed that the variation is associated with BChE 
genetically, although BChE is not the only plasma aspirin hydrolase.  
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As reported, aspirin hydrolases of erythrocytes (Reilly and FitzGerald 1988) 
and plasma (O'Brien 1968) hydrolyze aspirin in the systemic circulation in a first 
order process. Enzymes able to hydrolyze aspirin are present in blood and have been 
termed “aspirin esterases”. Most publications in this field seem to ignore the 
contribution of the red cell to aspirin hydrolysis. Several previous reports have 
mentioned in passing that whole blood has a higher enzymatic activity than serum or 
plasma, but the contribution from the cellular fraction has not been extensively 
studied (Harthon and Hedstrom 1971). The first time Rylance & Wallace showed that 
there was no significant correlation between the enzyme levels in erythrocytes and 
plasma suggesting that the enzyme inside the red cell and plasma was different 
(Rylance and Wallace 1981). Human erythrocytes are anucleate and without 
mitochondria in mammals. They live out a finite life span (120 days) and are unable 
to renew any of its critical enzymes and structural proteins, although it is able to 
repair some oxidative damage to its component parts. Erythrocytes quickly complete 
one cycle of circulation in an average of 20 seconds (Pierige, Serafini et al. 2008), 
which makes available to aspirin immediately after it is absorbed. In addition, aspirin 
permeates rapidly into the erythrocytes, almost within one minute (Ohsako, 
Matsumoto et al. 1993). Thus, erythrocytes are important in controlling aspirin 
hydrolysis in normal whole human blood. Erythrocyte aspirin hydrolase was first 
concluded as a membrane-bound acetylcholinesterase by Costello, P.B. et al. 
(Costello and Green 1982). But later they found it is located in cytosol, which is not 
affected by Ca2+ and other bivalent cations and is not acetylcholine esterase (Costello 
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and Green 1983). A 95,000 Dalton protein was partially purified as a major aspirin 
hydrolytic hydrolase in human erythrocytes. But the identity of the erythrocyte aspirin 
hydrolase is still unclear. They also found hematocrit positively correlated with the 
rate of aspirin hydrolysis (Costello, Caruana et al. 1984). An erythrocyte hydrolase 
was found to be defective in systemic lupus erythematosus (SLE), which resulted in 
reduced aspirin hydrolyzing capacity (Costello and Green 1986). In vitro studies 
reveal that about half of aspirin hydrolytic activity in blood is because of erythrocytes, 
which also consist with the phenomenon that  whole blood hydrolyzing aspirin faster 
than that of plasma about twofold (Costello, Caruana et al. 1984). 
A unique class of phospholipases A2 has a property for deacylation of 
phospholipids Sn-2 acetyl residue of platelet-activating factor (PAF), called platelet-
activating factor acetylhydrolase (PAFAH) (McIntyre, Prescott et al. 2009). Type I 
PAFAH, a unique serine esterase, is very specific for Sn-2 acetyl group hydrolysis 
and has significant homology with a divers family of microbial hydrolases which have 
a series of bacterial polysaccharide as substrates but not with any other mammalian 
proteins (Arai, Koizumi et al. 2002). Its tertiary structure resembles that of G-proteins 
(Ho, Swenson et al. 1997). Type I PAFAH is expressed in diverse human tissue and 
has undefined biological functions, although anti-apoptotic action was showed (Bonin, 
Ryan et al. 2004). 
In normal whole human blood, erythrocytes are the major place where aspirin 
is hydrolyzed. So it is important to identify and to characterize the aspirin hydrolases 
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from human erythrocytes. It will reveal the role of erythrocytes in modulation of anti-
platelet function of aspirin. 
4.2. Results  
4.2.1. Erythrocytes account for half or more of blood aspirin hydrolytic activity, 
which varies inter-individually. 
Erythrocytes (Costello and Green 1982) and plasma (O'Brien 1968) were both 
believed important in controlling aspirin hydrolysis in human circulation. I compared 
contribution of erythrocytes and plasma to whole blood aspirin hydrolytic activity in 
13 donors (Figure 34). Contributions of whole blood aspirin hydrolytic activity by 
plasma and erythrocytes varied from donor to donor. I also did time course 
comparison of aspirin hydrolytic activity of erythrocytes and plasma from a single 
donor (Figure 35). Erythrocytes accounted for most of whole blood aspirin hydrolytic 
activity comparing to plasma in this single donor. I also investigated erythrocyte 
aspirin hydrolytic activity among eleven donors (Figure 36). Washed erythrocytes 
(108) from different donors were analyzed for aspirin hydrolytic activity. Over a 2-
fold difference was found among donor cells. It suggests that erythrocytes are 
important in inactivating circulating aspirin, but the donor cells, too, vary on this 
attribute.  
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Figure 34. Comparisons of Aspirin hydrolytic activity of plasma and 
erythrocytes among 13 individuals. Plasma and erythrocytes were separated from 
same donor’s whole blood. Same volume (10 µl) of plasma and erythrocytes were 
measured for aspirinase activity as described in Chapter II. Data are present as mean ± 
S.D., n=3. 
 
 
 
 
 
 
 
 
 
 
83 
 
 
 
0 100 200 300
0
1
2
3
4
5
Whole blood
Erythrocytes
Plasma
Time (min)
Sa
lic
yl
ic
 a
ci
d 
(n
m
ol
)
 
Figure 35. Time course hydrolysis of aspirin by whole blood, erythrocytes and 
plasma. Erythrocytes were isolated from ACD anti-aggregated blood by 
centrifugation at 1,000×g for 30min at 4℃. W hite blood cells layer was carefully 
removed after plasma was collected. Volume ratio of erythrocytes to plasma was 
about 1 to 1. 4mM aspirin was incubated with whole blood, erythrocytes, or plasma in 
500µl at 37℃. 50µl (whole blood) or 25µl (erythrocytes and plasma) was taken out 
from incubation at each time point to stop the reaction, and enzymatically produced 
salicylic acid was quantified by RP-HPLC. Data are presented by mean ± S.D., n≥3. 
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Figure 36. Aspirin hydrolytic activity variation of erythrocytes. Washed 
erythrocytes (108) of different donors were measured for aspirin hydrolytic activity as 
described in Chapter II. Data are present as mean ± S.D., n=3. 
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4.2.2. Neither AChE nor BChE accounts for erythrocyte aspirin hydrolytic activity. 
Both AChE and BChE were examined and neither of them was found had 
relationship with erythrocyte aspirin hydrolytic activity (Figure 37). BChE is a plasma 
aspirin hydrolase, which synthesized by liver. If there is any BChE in erythrocytes is 
not well documented, but it could contaminate with cells. Although AChE was 
showed not related with aspirin hydrolytic activity of erythrocytes, I still confirmed 
the conclusion before I started erythrocyte aspirin hydrolase purification. I directly 
examined purified AChE from human erythrocytes for aspirin hydrolytic activity 
(Figure 37A). No aspirin hydrolytic activity was detected in the active AChE which 
confirmed by α-naphthyl acetate staining. I also determined BChE amount by 
comparing with BChE standard (Figure 37B), which cannot account for aspirin 
hydrolytic activity in erythrocytes. 
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Figure 37. Neither AChE nor BChE accounts for erythrocyte aspirin hydrolytic 
activity. (A) 0.4 μg of active purified AChE from erythrocytes was incubated with 4 
mM aspirin at 37℃ for 2 hours. Hydrolyzed aspirin in one hour was calculated by 
quantifying produced salicylic acid from aspirin by a HPLC based method. (B) BChE 
was non-detectable in 107 erythrocytes. I measured BChE activity by using 
butyrylthiocholine as a substrate and did western blotting for BChE in 107 
erythrocytes lysates. Data are present as mean ± S.D., n≥3. 
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4.2.3. Type I PAFAH is aspirin hydrolase of erythrocytes. 
I purified erythrocyte aspirin hydrolytic activity by a combination of two 
DEAE columns, HiTrap Q column, and a sephacryl s-200 column (Figure 38). The 
overall purification was 1,438-fold, and the recovery was 24% (Table 2). At the final 
size exclusion chromatography, aspirin hydrolytic activity was eluted asymmetrically 
with peak activity in fraction 42 (Figure 39A). SDS-PAGE was performed and 
followed by Coomassie blue staining for fraction 35 to 45 (Figure 39B). Arrows show 
bands co-located with the activity. Suspected bands were cut and identified by nano 
LC/MS (Figure 39C). PAFAH1B was identified with 5 peptides and 27% coverage as 
the only hydrolase in the material. Western blotting for PAFAH1B2 and PAFAH1B3 
was performed in the gel filtration fractions where aspirin hydrolytic activity existed 
(Figure 39D). Both PAFAH1B2 and PAFAH1B3 were detected in the activity 
fractions and correlated with activity. In order to confirm type I PAFAH was an 
erythrocyte aspirin hydrolase, I overexpressed one of catalytic subunits of type I 
PAFAH (α2) and measured aspirin hydrolytic activity in the HEK 293T cells (Figure 
40). Western blotting for PAFAH1B2 was performed to confirm overexpression. 
Aspirin hydrolytic activity was examined in the presence or absence of inhibitors in 
lysates of same number of overexpressed or normal cells. Aspirin hydrolytic activity 
of PAFAH1B2 overexpressed HEK 293T cells was found 6-fold more than that of 
control HEK 293T cells, which can be inhibited to control level by 2mM DTNB. 
2mM MAFP was found to totally inhibit aspirin hydrolytic activity both in 
overexpressed or control HEK 293T cells. PAF hydrolytic activity was also examined 
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as above (Figure 41). It was found the same as aspirin hydrolytic activity. I also 
examined recombinant PAFAH1B2 for aspirin hydrolytic activity (Figure 42). 0.1μg, 
0.2μg, and 0.4μg of recombinant PAFAH1B2 were incubated with 4mM aspirin in the 
presence of 40mM DTT at 37℃ for 1 hour. Hydrolyzed aspirin increased in a 
concentration dependent manner. I also overexpressed PAFAH1B3 in HEK 293 cells, 
same results as PAFAH1B2 (Figure 43). Effects of NaF, a PAFAH I inhibitor, on 
purified erythrocytes aspirin hydrolase were examined (Figure 44). NaF inhibited 
aspirin hydrolytic activity of erythrocytes in a dose dependent manner. This result in 
consisted with the inhibitory effects of NaF on PAF hydrolytic activity (Stafforini, 
Rollins et al. 1993). I also found a minor aspirin hydrolytic activity peak when I did 
the first DEAE chromatography (Figure 38A). This phenomenon was consistent with 
that showed by Ken Karasawa et al. , although they used pig erythrocytes as a enzyme 
source (Karasawa, Shirakura et al. 2005). I purified it as a single band in native PAGE, 
but several bands formed by SDS-PAGE (Figure 45). I found PAFAH1B2 as one of 
these bands by western blotting and identified all other bands as N-acylaminoacyl-
peptide hydrolase (APEH) by mass spectrometry. I excluded APEH as an aspirin 
hydrolase by overexpression (Figure 46). APEH was overexpressed in HEK 293T 
cells, which confirmed by both western blotting and APEH activity (Figure 46A). 
However, no increase of aspirin hydrolytic activity was detected in the APEH 
overexpressed cells comparing with control cells (Figure 46B). It suggests that type I 
PAFAH accounts for aspirin hydrolytic activity of erythrocytes. 
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Figure 38. Elution profile of erythrocyte aspirin hydrolase purification. (A) 0-0.5 
M NaCl linear gradient elution of EDAE chromatography. (B) 0-0.1 M NaCl linear 
gradient elution of EDAE chromatography. (C) 0-0.1 M NaCl linear gradient elution 
of HiTrap Q chromatography. (D) Sephacryl S-200 gel filtration chromatography. 
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Table 2 
 
Total 
protein 
(mg) 
Total 
activity 
(nmol/hour) 
Specific activity 
(nmol/mg/hour) 
Purification 
(fold) 
Recovery 
(%) 
RBC lysate 10485.00  129339.65  12.33  1  100.00  
DEAE 
binding 
4100.00  99288.60  24.82  2  76.77  
DEAE I 91.39  60012.00  656.66  53  46.40  
DEAE II 41.56  37083.70  892.29  72  28.67  
HiTrap Q 
FF 
12.40  34260.00  2762.90  224  26.49  
Sephacryl 
S-200 
1.80  31924.01  17735.60  1438  24.68  
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Figure 39. Type I Platelet-activating Factor acetylhydrolase is the primary 
erythrocyte aspirin hydrolase. (A) Aspirin hydrolytic activity was measured in gel 
filtration chromatography fractions. Maximal activity was eluted in fraction 41 to 43 
where a size of 70 KDa located. (B) SDS-PAGE for gel filtration fractions (35-45). 10 
µl of each fraction was isolated by 4-15% gradient SDS-PAGE and followed by 
Commassie Blue staining. Arrow shows bands which were analyzed by mass 
spectrometry. (C) Results of mass spectrometry. PAFAH1B2 was identified by 5 
peptides (underlined) with 27% coverage. (D) Western blotting for PAFAH1B2&3 in 
fraction 35 to 45. 
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Figure 40. Overexpression of PAFAH1B2 increases aspirin hydrolytic activity of 
cell lycates. PAFAH1B2 was overexpressed in HEK 293K cells. Western blotting 
was performed to confirm PAFAH1B2 overexpression. Aspirin hydrolytic activity 
was examined in the cell lysates in the presence or absence of inhibitors. Data are 
present as mean ± S.D., n=3. 
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Figure 41. Overexpression of PAFAH1B2 increases PAF acetylhydrolase activity 
of cell lycates. PAFAH1B2 was overexpressed in HEK 293K cells. Western blotting 
was performed to confirm PAFAH1B2 overexpression. PAF acetylhydrolase activity 
was examined in the cell lysates in the presence or absence of inhibitors. Data are 
present as mean ± S.D., n=3. 
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Figure 42. Recombinant PAFAH1B2 hydrolyzes aspirin. 0.1 μg, 0.2 μg, and 0.4 μg 
recombinant PAFAH1B2 were incubated with 4 mM aspirin at 37℃ for 2 hours. 
Salicylic acid product was measured by RP-HPLC. Aspirin hydrolysis was found a 
dose dependent increase. Data are present as mean ± S.D., n=3. 
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Figure 43. Overexpression of PAFAH1B3 increases aspirin hydrolytic activity of 
cell lycates. PAFAH1B3 was overexpressed in HEK 293K cells. Western blotting 
was performed to confirm PAFAH1B3 overexpression. Aspirin hydrolytic activity 
was examined in the cell lysates in the presence or absence of inhibitors. Data are 
present as mean ± S.D., n=3. 
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Figure 44. NaF inhibits aspirin hydrolytic activity of purified erythrocyte aspirin 
hydrolase. 4 mM aspirin was incubated with NaF of different concentration (0 mM to 
50 mM). Aspirin hydrolytic activity was inhibited by NaF in a dose dependent manner. 
Data are present as mean ± S.D., n=3. 
 
 
 
 
 
 
 
 
 
 
 
97 
 
 
 
 
 
 
 
 
 
Figure 45. PAFAH1B2 was detected in purified minor part of erythrocyte aspirin 
hydrolytic activity.  Minor part of aspirin hydrolytic activity from the first DEAE 
chromatography (Supplemental. Fig. 2A) was purified by cation exachange and gel 
filtration chromatography. Native PAGE after Coomassie blue staining showed a 
single band. The same amount of purified minor part of aspirin hydrolytic activity was 
subjected onto SDS-PAGE and several bands were separated and stained by 
Coomassie blue. PAFAH1B2 was detected by western blotting. All other bands were 
identified as APEH by mass spectrometry. 
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Figure 46. APEH does not have aspirin hydrolytic activity. (A) APEH was 
overexpressed in HEK 293T cells. Both western blotting for APEH and APEH 
activity assay were performed to confirm that APEH was overexpressed successfully. 
(B) Aspirin hydrolytic activity was examined in cell lysates of both APEH 
overexpressed and normal HEK 293T cells. No increased aspirin hydrolytic activity 
was found. Data are present as mean ± S.D., n≥3. 
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4.2.4. Type I PAFAH hydrolyzes aspirin efficiently. 
Effect of PAF on aspirin hydrolysis by type I PAFAH was examined.  I 
verified that erythrocyte PAF acetylhydrolase was an appropriate candidate aspirin 
hydrolase by testing aspirin hydrolysis by PAFAH1B2 because, at least for PAF at 
low concentrations, the type I complex is more effective as the PAFAH1B2 
homodimer or PAFAH1B2 and PAFAH1B3 heterodimer (Manya, Aoki et al. 1999; 
Karasawa, Shirakura et al. 2005) than the enzyme containing the PAFAH1B3 
homodimer. Recombinant PAFAH1B2 effectively hydrolyzed aspirin, and its rate 
varied with substrate concentration that was well described by the Michaelis-Menten 
equation (Figure 47). The Km was determined to be 1.13 ± 0.57 mM and its Vmax 
was 21.4 ± 2.95 nmol/h/µg. The enzyme purified from erythrocytes displayed an 
apparent Km for aspirin of 2.17 ± 0.65 mM with a corresponding Vmax of 66.05 ± 
7.18 nmol/h/µg, suggesting the recombinant material was not fully active. 
Butyrylcholinesterase is the most completely characterized soluble enzyme to 
hydrolyze aspirin, which hydrolyzed aspirin with a Km of 2.78 ± 0.59 mM and a 
Vmax of 56.36 ± 4.78 nmol/h/µg. I determined whether the acetyl group of PAF and 
aspirin were likely hydrolyzed in the same active site of the type I PAF 
acetylhydrolase, and tested the effect of PAF on aspirin hydrolysis by the purified 
erythrocyte enzyme and recombinant PAFAH1B2. I found that the short chain 
phospholipid inhibited hydrolysis of the xenobiotic aspirin substrate by both enzymes 
(Figure 48), and that this inhibition was competitive for both enzymes. The calculated 
Ki for PAF inhibition of aspirin hydrolysis for the purified PAFAH1B2 was 0.47 mM, 
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whereas that for recombinant PAFAH1B2 was 0.29 mM. This indicates a strong 
preference for PAF compared with aspirin by recombinant PAFAH1B2.  
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Figure 47. A calculated Michaelis-Menten curve of aspirin hydrolysase by 
nonlinear regression analysis. BChE, purified erythrocyte aspirin hydrolase, or 
rPAFAH1B2 were incubated with different concentration of aspirin at 37°C for 1 
hour and followed salicylic acid quantification. Km of BChE is 2.78 mM. Km of 
PAFAH1B is 2.17 mM. Km of rPAFAH1B2 is 1.17 mM. Data was analyzed by prism 
4. 
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Figure 48. PAF competitively inhibits aspirin hydrolysis by erythrocyte aspirin 
hydrolase. Aspirin hydrolysis was measured in duplicates containing fixed amount 
purified type I PAFAH (400 ng) and varied aspirin (0.5–8 mM) in PBS buffer at pH 
7.2 in the absence or presence of 1 mM PAF. Purified erythrocyte aspirin hydrolase 
(right) or recombinant PAFAH1B2 (left) was incubated with aspirin of different 
concentration in the presence or absence of PAF at 37℃ for 2 hours followed by RP -
HPLC measurement. Lineweaver–Burke plot was converted from Michaelis-Menten 
plot. Ki value of purified erythrocyte aspirin hydrolase is 0.47 mM; Ki value of 
rPAFAH1B2 is 0.29 mM. Data was analyzed by prism 4. 
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4.2.5. Erythrocyte Aspirin Hydrolysis Varies among Individuals. 
The effectiveness of aspirin in inhibiting platelet function ex vivo varies 
among individuals and populations for unknown reasons (Patrono 2003; Adebayo, 
Williams et al. 2007; Fitzgerald and Maree 2007; Kotani, Kimura et al. 2010). I found 
that hydrolysis varied by over 2-fold when erythrocytes were prepared from 10 
different donors (Figure 49A). Hydrolysis in lysates from a single donor, however, 
was reproducible (not shown). I assessed variation of type I PAF acetylhydrolase 
subunits in the blood of these donors to find that total PAFAH1B2 also varied among 
donors, whereas the PAFAH1B3 content was uniform (Figure 49B). Moreover, 
variation of PAFAH1B2, and not PAFAH1B3, content correlated with aspirin 
hydrolysis, suggesting the PAFAH1B2 containing type I PAF acetylhydrolase is the 
most effective aspirin hydrolase of erythrocytes, and blood. 
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Figure 49. PAFAH1B2 and aspirin hydrolytic activity vary among donors. (A) 
Variation in the inter-individual rate of erythrocyte hydrolysis of aspirin. Aspirin 
hydrolytic activity was measured as described in Chapter II erythrocytes (108) 
obtained from 10 random blood donors. Data are presented by mean ± S.D., n =3. (B) 
PAFAH1B2 varied among blood donors. PAFAH1B2 (upper panel), PAFAH1B3 
(lower panel), or β-actin in samples from the donors in panel A were determined by 
immunoblotting as described under chapter II. 
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4.3. Discussion 
In this chapter, I purified and identified erythrocyte aspirinase as type I 
PAFAH. I also determined its apparent Km as 2.17 ± 0.59 mM using aspirin as a 
substrate. The Ki is 0.47 mM using 1 mM PAF as a competitive inhibitor. I 
discovered variation of erythrocyte aspirinase activity among individuals, which 
related to PAFAH1B2. 
Aspirin hydrolysis was measured by RP-HPLC based quantifying salicylate 
product, which is more accurate than a spectrophotometer based method because the 
salicylate product of aspirin is not only derived from hydrolysis but also from 
acetylation. Erythrocyte aspirin hydrolase contributes more than half of aspirin 
hydrolysis activity in blood (Costello, Caruana et al. 1984). My data showed 
erythrocytes had a higher aspirin hydrolytic activity compared to plasma and 
contribute half or more to aspirin hydrolysis in whole blood. This, however, was only 
examined from a single donor, and the ratio of hydrolysis in plasma to cells may vary 
among donors. Albumin controls aspirin entering erythrocytes by reversibly binding 
and transporting this amphipathic molecule (Costello and Green 1987). Although 
albumin slowed aspirin hydrolysis in erythrocytes, it may increase the chance of 
plasma aspirin hydrolysis. Erythrocytes readily accumulate aspirin through band 3, an 
anion channel, from their environment (Ohsako, Matsumoto et al. 1993), and aspirin 
hydrolysis by erythrocyte lysates exceeded that by plasma enzymes. Previously, I 
identified the plasma enzymes as buytrylcholinesterase and a second equally effective, 
unidentified activity. The activity of aspirin hydrolysis by both activities varied 
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significantly in donor plasma, and the effectiveness of erythrocyte lysates in 
hydrolyzing aspirin also varied by several fold among donors. This difference in the 
ability to rapidly clear vascular aspirin by hydrolysis may be a reason of the apparent 
variation in the effectiveness of aspirin prophylaxis, aspirin resistance, among 
populations and individuals (Maree, Cox et al. 2007; Patrono and Rocca 2007). 
I identified a single major activity of aspirin hydrolyitic activity in 
erythrocytes as type I PAF acetylhydrolase by purifying the activities from 
erythrocyte lysates that hydrolyze aspirin. I discovered this consists of the PAF 
acetylhydrolase type I complex, but also apparently a second activity (ies) isolated by 
a larger protein or complex resolved by size separation whose identity was proved as 
PAFAH1B2. The PAF acetylhydrolase complex did not migrate as a single entity, but 
the type I PAFAH containing PAFAH1B3 homodimers differs modestly compared to 
the complex containing PAFAH1B2 homodimers (Karasawa, Shirakura et al. 2005). 
The two different activity complexes of type I PAFAH were also found by Karasawa, 
K et al. They purified type I PAFAH and also found two activities, although they used 
PAF as a substrate to purify the activity from pig erythrocytes (Karasawa, Shirakura 
et al. 2005). And they found that it was not possible to purify the minor activity (they 
called it as fraction X) to homogeneity. Their findings supported our results that 
purified minor erythrocyte aspirin hydrolytic activity was found a complex with 
abundance of APEH, and PAFAH1B2 was also detected in it by western blot. And 
this kind of complex was also found in platelets and neutrophils.  
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Aspirin hydrolytic activity is largely a property of erythrocytes, which quickly 
internalizes it through prior to intracellular hydrolysis (Ohsako, Matsumoto et al. 
1993).  Diisopropylfluorophosphonate, like the methyl arachidonoyl 
fluorophosphonate used here, repressed erythrocyte hydrolysis of aspirin consistent 
with membrane-bound acetylcholinesterase (Costello and Green 1982).  Costello, P.B. 
et al. purified aspirin hydrolytic activity about 900-fold from a half saturated 
(NH4)2SO4 solution of erythrocyte lysates by DEAE sephacel chromatography. A 95 
KDa protein was isolated by SDS-PAGE as erythrocyte aspirin hydrolase, which is 
sulfhydryl group dependent but different from the nonspecific type D esterases 
(Costello and Green 1983). Type I PAFAH is a sulfhydryl group dependent enzyme 
and has a molecular weight of 29 or 30 KDa but not 95 KDa. I cannot reconcile our 
identification of 30 and 29 kDa PAF acetylhydrolases with this apparent molecular 
weight, but when nondenatured the type I PAF acetylhydrolase exits as a trimer of 
either homo- or heterodimers of 29 and 30 kDa catalytically active subunits together 
with a non-catalytic subunit LIS1 of 45 kDa (Hattori, Adachi et al. 1994). Costello, 
P.B. et al. most probably purified this as their erythrocyte aspirin hydrolytic activity. 
Recombinant PAFAH1B2 or lysates of HEK 293 cells transiently transfected with 
this gene hydrolyzed aspirin, aspirin and PAF competed with one another for 
hydrolysis, and hydrolysis was appropriately blocked by DTNB and 
diisopropylfluorophosphonate, established inhibitors of erythrocyte PAF 
acetylhydrolase (Stafforini, Rollins et al. 1993).  These data all give support to type I 
PAFAH as an aspirin hydrolase. 
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Over 100 million tons of aspirin is consumed per year (Warner and Mitchell 
2002) as anti-pyretic and anti-inflammatory therapeutics, and as a prophylaxis for 
major cardiovascular events. The pharmacokinetics show that ingested aspirin has 
only a short half-life in the circulation of approximately 20 min (Needs and Brooks 
1985; Higgs, Salmon et al. 1987). The primary medical target of the acetyl functional 
group  of acetylsalicylic acid is type I cyclooxygenase (prostaglandin H-synthase) 
(Roth, Stanford et al. 1975) of platelets that irreversibly inhibits production of the 
prostaglandin H2 precursor for platelet thromboxane formation and thereby sharply 
reduces platelet reactivity (Smith, DeWitt et al. 2000). Hydrolysis of aspirin, and 
hence control of circulating aspirin levels, varies greatly among individuals and is 
increased in individuals with inflammatory phenotypes (Williams, Asad et al. 1987; 
Akopov, Grigorian et al. 1992; Puche, Gomez-Valverde et al. 1993; Gresner, Dolnik 
et al. 2006; Kotani, Kimura et al. 2010). As a subsequence, efficiency of aspirin on 
anti-platelet also varies among individuals accordingly.  
Type I PAF acetylhydrolase was initially purified from bovine brain (Hattori, 
Arai et al. 1993) and determined to be a unique esterase (Hattori, Adachi et al. 1994; 
Ho, Swenson et al. 1997) unrelated to the other two members of the group VII 
phospholipase A2 family (Six and Dennis 2000). Subsequently, red blood cells were 
found to richly express the type I PAF acetylhydrolase (Karasawa, Shirakura et al. 
2005). This identification was consistent with the low molecular weight of the 
enzyme purified from erythrocytes found to be sensitive to NaF, DTNB, and 
diisopropylfluorophosphonate (Stafforini, Rollins et al. 1993). Physiological function 
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of type I PAFAH is still under exploriation. PAF (1-O-alkyl-2-acetyl-sn-glycero-3-
phosphocholine), a lipid mediator, is believed its physiological substrate, since PAF 
hydrolyzing activity was used to purify type I PAFAH. PAFAH1B2 was showed as a 
serine esterase with an activity serine 47 residue and had some homology to PAF 
receptor (Hattori, Adachi et al. 1994). Animal studies showed PAFAH1B involved in 
spermatogenesis (Koizumi, Yamaguchi et al. 2003; Yan, Assadi et al. 2003) and 
neuronal migration (Manya, Aoki et al. 1998).  
Aspirin as an artificial substrate of type I PAFAH may affect those 
physiological functions of people with long term aspirin medication. However, the 
type I PAF acetylhydrolase serves no known role in erythrocytes because erythrocytes 
neither synthesize the phospholipid autocoid PAF (1-O-alkyl-2-acetyl-sn-glycero-3-
phosphocholine) nor readily accumulate it from their environment (Chen, Yang et al. 
2007). This is critical because while other PAF acetylhydrolases act on oxidized 
phospholipids (Stremler, Stafforini et al. 1989), the type I enzyme is tightly 
constrained to acetyl hydrolysis (Ho, Sheffield et al. 1999). Genetic ablation of either 
the PAFAH1B2 or PAFAH1B3 gene does not identify a physiologic role for this 
enzyme complex because neither displays defective erythrocyte function (Koizumi, 
Yamaguchi et al. 2003). Still, the crystal structure of this esterase, like the structural 
homolog in Streptomyeces exfoliates (Wei, Swenson et al. 1998), shows that only 
acetyl esters are accommodated in the active site (Ho, Swenson et al. 1997; Ho, 
Sheffield et al. 1999), and may allow access for the acetyl functional group of aspirin. 
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Aspirin has been a popular and effective drug over the past century or even 
now, but the agents responsible for its rapid turnover in the circulation have not been 
identified. Purification shows the type I PAF acetylhydrolase esterase complex is a 
major component of aspirin hydrolysis activity in blood. The ability to accept an 
acetyl functional group is likely important in acceptance of aspirin as a substrate by 
this enzyme complex, but the two catalytic subunits have distinct requirements for the 
glycerophospholipid of acetylated phospholipids (Manya, Aoki et al. 1999) so 
acceptance of aspirin must involve more than simple recognition of the acetyl group. 
Individuals have different abilities to hydrolyze aspirin in plasma and in erythrocytes, 
the major contributors to aspirin turnover in blood, and this may be a component of 
the variation in aspirin effectiveness, or aspirin “resistance” (Marshall, Williams et al. 
1997; Mueller, Salat et al. 1997; Stejskal, Proskova et al. 2004; Tantry, Bliden et al. 
2005).                                                                
In conclusion, type I PAFAH is the aspirin hydrolase of erythrocytes. Using 
aspirin as a substrate, kinetic properties of type I PAFAH have been characterized. 
Aspirin hydrolytic activity of erythrocytes varies among individuals, which related 
with PAFAH1B2. 
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CHAPTER V 
5. ELUCIDATION OF THE RELATIONSHIP BETWEEN ASPIRIN 
HYDROLASES AND ASPIRIN EFFICACY 
 
5.1.  Introduction 
In Western societies, the leading causes of death and the increasing costs of 
health care are cardiovascular diseases (CVD), especially myocardial infarction (Sans, 
Kesteloot et al. 1997). It was reported that aspirin (300 mg/day) reduced total 
mortality in patients one year after myocardial infarction by 25.7%, although it was 
not statistically significant at conventional levels (p > 0.05) (Elwood, Cochrane et al. 
1974). However, it first suggested that administration of aspirin regularly may prevent 
a second heart attack. Nowadays aspirin is widely used as a prophylaxis reagent of 
cardiovascular disease, which is due to the major effect of aspirin, anti-platelet 
function.  This function is accredited to the acetyl group of aspirin which irreversibly 
acetylates cyclooxygenase-1 (COX-1) at its 530 serine residual to inhibit 
thromboxane A2 production (Szczeklik, Gryglewski et al. 1979). Preexisting risk 
factors, such as atherosclerotic alterations of the vessel wall, mainly determine the 
possibility of thrombotic events, which may through hyper reactive platelets (Gawaz 
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2004). As we know, active platelets produce lots of thromboxane. By measuring 
levels of plasma thromboxane in circulation, people found that platelets play 
important roles in unstable angina (Fitzgerald, Roy et al. 1986). Aspirin inhibits 
platelet activation by inhibiting formation of thromboxane, which will benefit those 
diseases. But 5–45% of patients with unstable angina and 5–65% of patients with 
stroke (McKee, Sane et al. 2002; FitzGerald 2003; Wang, Aucoin-Barry et al. 2003; 
Alberts, Bergman et al. 2004; Mason, Jacobs et al. 2005; Sztriha, Sas et al. 2005) are 
considered aspirin “resistant”. This makes aspirin impotence, although it an idea 
prevention medicine of heart diseases. 
However, the benefit effects of aspirin on CVD was thought has nothing to do 
with inhibition of thromboxane (Bertele, Tomasiak et al. 1982), because thromboxane 
inhibiting effects are only detectable when high dose of aspirin is medicated (Undas, 
Brummel et al. 2001), as well as increased fibrinolytic activity and anti-inflammatory 
effects (Cattaneo 2004). High-dose aspirin was reported better than low-dose aspirin 
in stroke prevention effect (Tohgi, Konno et al. 1992), which was believed to be due 
to reduced response of platelets to aspirin in these survived patients after the acute 
heart attack (Grotemeyer 1991). So dosing of aspirin is pivotal and the mechanism of 
aspirin is complicated.  Variation of response to aspirin in these patients (Helgason, 
Bolin et al. 1994) was confirmed by Gurbel et al. (Gurbel, Bliden et al. 2007). So 
there must be a certain group of patients in Gurbel’s study whose platelets are 
insufficient inhibited by the same dose of aspirin (Schror, Weber et al. 2006). 
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No matter what the mechanism of aspirin is, anti-platelet function of aspirin is 
well documented and dosing of aspirin is critical. Blood aspirin hydrolases are 
important in controlling exposure time of platelet into aspirin. I have shown that 
significant aspirin hydrolytic activity variation in plasma as well as in erythrocytes. I 
identified blood aspirin hydrolases as BChE and type I PAFAH. How these aspirin 
hydrolases modulate anti-platelet function of aspirin is still undefined. I investigated 
effects of both plasma aspirin hydrolase and erythrocyte aspirin hydroalse on anti-
platelet function of aspirin and found variation of aspirin hydrolytic activity varied 
aspirin efficacy in vitro. 
 
5.2. Results  
5.2.1.  Anti-platelet function of aspirin is dose dependent. 
Aspirin irreversibly acetylates cyclooxygenase-1 of platelets which inhibits 
thromboxane A2 production to inhibit platelet activation. When platelets are activated, 
they will aggregate and release other agonists such as ADP, a potent agonist, to recruit 
other platelets as well as ATP for other cells of the blood (Sung, Young et al. 1985; 
Greenberg, Di Virgilio et al. 1988). I investigated concentration effect of aspirin on 
platelet aggregation (Figure 50). 108 washed platelets in 500μl HBSS buffer were 
incubated with aspirin of different concentration (25μM, 33μM, and 50μM) at 37°C 
for 5 min and followed stimulation by 5μg/ml collagen. Aspirin inhibited platelet 
aggregation in a concentration dependent manner with 33μM aspirin being the lowest 
concentration to inhibit platelet aggregation. 
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Figure 50. Anti-platelet effect of aspirin is dose dependent. Different concentration 
of aspirin treated washed platelets (108) were stimulated by 5 μg/ml collagen. Platelet 
aggregation was recorded by optical aggregometer. n=8. 
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5.2.2.  Variation of plasma aspirin hydrolytic activity modulates anti-platelet 
function of aspirin. 
Since we knew that significant variation of plasma aspirin hydrolytic activity 
existed in population, I also investigated the effect of the variation on anti-platelet 
function of aspirin. I first chose platelet poor plasmas (PPP) with different aspirin 
hydrolytic activities. PPP of donor 3 had high level of aspirin hydrolytic activity; PPP 
of donor 6 had low level of aspirin hydrolytic activity (Figure 27C). I pre-incubated 
33μM aspirin with these PPP at 37°C for 30 min and then performed platelet 
aggregation inhibition experiment (Figure 51). PPP of donor 3, which had high level 
of aspirin hydrolytic activity, impaired more anti-platelet function of aspirin than that 
of PPP of donor 6, which had low level of aspirin hydrolytic activity. And I also knew 
that variation of plasma aspirin hydrolytic activity is due to BChE. So I examined 
effect of BChE on anti-platelet function of aspirin. I pre-incubated 33 μM aspirin with 
2 μg BChE at 37°C for 30 min and followed stimulation by 5 μg/ml collagen (Figure 
52). Comparing with control, anti-platelet effect of aspirin was impaired by pre-
incubation with BChE. It suggests that variation of plasma aspirin hydrolytic activity 
can modulate anti-platelet function of aspirin.  
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Figure 51. Plasma aspirin hydrolytic activity modulates anti-platelet function of 
aspirin. Aspirin was pre-incubated with plasma (400 μl) of different donors with 
different aspirin hydrolytic activity at 37°C for 30 min. 108 washed platelets in 100μl 
were added into the plasma. After 5min incubation, platelets were stimulated by 5 
μg/ml collagen. n=3. 
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Figure 52. BChE suppresses anti-platelet function of aspirin. Aspirin was pre-
incubated with 2 μg BChE at 37°C for 30 min. 108 washed platelets in 100 μl were 
added into the plasma. After 5min incubation, platelets were stimulated by 5 μg/ml 
collagen. n=3. 
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5.2.3. Erythrocyte aspirin hydrolase contributes aspirin inactivation. 
Erythrocytes as a major player of blood aspirin hydrolytic activity are also 
found variation among population but not that much as that of plasma (Figure 36). I 
examined effect of erythrocytes on anti-platelet function of aspirin. I found that the 
major effect of erythrocytes was due to aspirin hydrolase. Erythrocytes quickly 
inactivated aspirin and reduced its anti-platelet function. And this aspirin inactivating 
effect by erythrocytes can be inhibited by 50 mM NaF, which inhibits type I PAFAH. 
Aspirin was pre-incubated with 1 μl washed erythrocytes for 30min at 37℃ or 
without pre-incubation and then the erythrocytes and aspirin mixture was added to 
108 washed platelets (450 μl) for another 5 min which the aspirin would have been at 
a final concentration of 50 μM. Platelets were stimulated by 5 μg/ml collagen (Figure 
53). 30 min incubation with erythrocytes totally eliminated 50 μM aspirin’s anti-
platelet function. NaF inhibited the erythrocyte effect on aspirin’s anti-platelet 
function (Figure 54) when erythrocytes were pretreated with the type I PAFAH 
inhibitor, 50 mM NaF, for 30 min. Aspirin incubated with NaF treated erythrocytes 
still showed 20% platelet inhibition ability comparing to that of normal erythrocytes. 
Aspirin hydrolytic activity was examined in NaF treated erythrocytes. Comparing to 
normal erythrocytes, aspirin hydrolytic activity of 50 mM NaF treated erythrocytes 
was found inhibited by 60%, which suggested negative modulation effect of 
erythrocytes on aspirin’s anti-platelet function was due to its aspirin hydrolytic 
activity.  
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Figure 53. Erythrocytes suppress anti-platelet function of aspirin. 1 μl 
erythrocytes were incubated with aspirin at 37°C for 30 min and then were put into 
washed platelets (108 in 450 μl) for another 5min. Platelets were stimulated by 5 
μg/ml collagen. 
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Figure 54. Aspirin hydrolase of erythrocytes is important in suppressing anti-
platelet function of aspirin. Erythrocytes were treated with 50 mM NaF, which 
inhibited 60% of their activity. 1 μl NaF treated or normal erythrocytes were 
incubated with aspirin for 30 min and then were added into washed platelets (108 in 
450 μl) for another 5 min. Platelets were stimulated by 5 μg/ml collagen. 
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5.2.4. Erythrocytes reduce aspirin inhibition of platelet thromboxane B2 production. 
In order to make sure that the negative effect of erythrocyte on aspirin’s anti-
platelet function is because of aspirin hydrolysis. TxB2, a metabolite of TxA2, was 
examined. Production of thromboxane B2 in platelets was reduced by 25 µM aspirin, 
but abolished by 50 µM aspirin (Figure 55, comparison 1). Erythrocytes neither made 
thromboxane B2, nor suppressed its production by collagen-activated platelets. 
However, erythrocytes erythrocytes greatly reduced the effect of aspirin on platelet 
thromboxane B2 production: erythrocytes preincubated with aspirin reduced the 
effectiveness of this drug and allowed platelet synthesis of the prostanoid to recover 
(Figure 55, comparison 2). Aspirin incubated with erythrocytes for 0 time was 
inhibitory, but aspirin preincubated with erythrocytes for 30 min was significantly less 
effective in blocking platelet thromboxane B2 production (Figure 55, comparison 3). 
In fact, aspirin preincubated with erythrocytes was almost completely ineffective as a 
platelet inhibitor. NaF addition to erythrocytes along with aspirin reduced the 
inhibitory effect of erythrocytes on aspirin, and again allowed aspirin to inhibit 
platelet thromboxane B2 production (Figure 55, comparison 4). 
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Figure 55. Erythrocytes reduce aspirin inhibition of platelet thromboxane B2 
production. Platelets were stimulated by 5 μg/ml of collagen after the stated 
treatments. Supernatants were collected and thromboxane B2, the stable metabolite of 
thromboxane A2, was measured by enzyme-linked immunoassay. Numbered 
comparisons are defined in the text and the data are present as mean ± S.D., n ≥ 3. 
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5.3.  Discussion 
Aspirin has significantly inhibits platelet activation. This effect occurs quickly 
and depends on the dose of aspirin. Blood aspirin hydrolases, whether in plasma or 
within erythrocytes, play an important role in controlling anti-platelet function of 
aspirin. I elucidated the relationship between blood aspirin hydrolases and anti-
platelet function of aspirin by in vitro experiments. My work showed that variation of 
blood aspirin hydrolytic activity can vary significantly.  
Aspirin is calculated to increase to 44 µM in plasma one minute after a single 
200 mg dose, with a real concentration of 13 µM measured 5 minutes after the oral 
dose (Higgs, Salmon et al. 1987). I found that 33 µM aspirin effectively suppressed 
washed platelet aggregation and that this inhibition was not linear in this immediate 
range, as previously found (FitzGerald, Maas et al. 1983). Platelets experiencing 
aspirin in plasma were less efficiently inhibited than in its absence, and this loss of 
potency was most pronounced in plasma of an individual with high 
butyrylcholinesterase activity and conversely was less in plasma of a donor with low 
activity. These results indicate that variation of plasma butyrylcholinesterase occurs 
over a range relevant to physiologic aspirin concentrations. 
Platelet function was usually measured by light transmission aggregometer 
and platelets were stimulated by one particular agonist, collagen. There are few 
erythrocytes in many platelet function assays, which overlook effect of erythrocytes 
on platelet function and on aspirin’s anti-platelet function. This may not capture or 
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reflect the real episode of aspirin’s anti-platelet function. Erythrocytes markedly 
increase platelet reactivity (Santos, Valles et al. 1997) and reduce the antiplatelet 
actions of aspirin (Valles, Santos et al. 1998). Taking into consideration of possible 
effects of erythrocytes in blood on aspirin, erythrocyte aspirin hydrolase may 
influence efficacy of aspirin on the platelet-dependent hemostatic process. I also 
found that erythrocytes impaired aspirin’s anti-platelet function by hydrolyzing 
aspirin.  
Aspirin is a widely used drug to prevent cardiovascular and thrombotic 
diseases. However, in recent decade more cases of aspirin treatment failure drew our 
attention, which was so called “aspirin resistance”. Aspirin “resistance” is a 
considerable clinical concern which descript phenomenon such as a reduced anti-
platelet activity of aspirin or lacking benefit from aspirin. Aspirin resistance in 
population was reported proximately 8-45% of total aspirin medication cases 
(Grotemeyer 1991; Grotemeyer, Scharafinski et al. 1993; Helgason, Tortorice et al. 
1993; Gum, Kottke-Marchant et al. 2001). Many reasons are proposed to explain 
“aspirin resistance”, which makes it a very random event (Fontana, Nolli et al. 2006; 
Gurbel, Bliden et al. 2007) and still a matter of debate. One of pharmacokinetic 
reasons, insufficient bioavailability, could be more reasonable and fundamental for 
“aspirin resistance” because of aspirin’s short half-life (15-20 min) and low dose 
usage (75-81 mg/day). Insufficient bioavailability is always a reason for less efficacy 
of any drug, including aspirin. Phase I biotransformation metabolism of aspirin in 
blood remains undefined. Widely believed so-called non-specific esterases catalyze 
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aspirin hydrolysis without further explanation. Understanding aspirin metabolism will 
contribute to improving its bioavailability, and help to reduce aspirin “resistance”. I 
identified blood aspirin hydrolases and characterized the role in anti-platelet function 
of aspirin. Aspirin administrated at a small dose is more prone to subject a possibly 
low bioavailability, which was supported by the fact that a plain preparation of aspirin 
is more effective over an enteric-coated preparation of it (Cox, Maree et al. 2006). In 
addition, aspirin has a very short half-life about 20 min which may be shorter in low 
dose aspirin medication. This means newly produced platelets during the intervals of 
medication will still have the active COX-1 and synthesize bioactive TxA2 to trigger 
platelet activation. High aspirin hydrolytic activity reduces intact aspirin access to 
COX-1 in platelets. My findings reveal that significant variation of blood aspirin 
hydrolytic activity significantly modulates anti-platelet function or ability of aspirin.  
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CHAPTER VI 
6. CONCLUSIONS AND DISCUSSIONS 
 
Blood aspirin hydrolases were purified, identified, and characterized. RP-
HPLC analysis of the product salicylic acid with an internal standard showed plasma 
hydrolysis of aspirin varied 12-fold variation among 2,275 individuals.  Genome-wide 
association analysis using serum aspirin hydrolytic activity from 2,275 individuals 
showed a genetic component to aspirin hydrolytic variation, and that only BChE 
significantly associated to aspirin variation. However, plasma from an individual with 
an inactivating point mutation in BChE effectively hydrolyzed aspirin. A non-BChE 
aspirin hydrolase was found in plasma, which can be distinguished from BChE by 
procainamide and oxidized ATP. Erythrocyte aspirin hydrolase was purified by 1400-
fold and type I PAF acetylhydrolase was identified as a candidate aspirinase by mass 
spectrometry. Recombinant PAFAH1B2 and PAFAH1B hydrolyzed aspirin and 
aspirin was effectively hydrolyzed in cells ectopically expressing PAFAH1B2 or 
PAFAH1B3. Oxidized ATP inhibits recombinant PAFAH1B2, and it reduces aspirin 
hydrolysis in plasma. Type I PAFAH also accounts for non-BChE plasma aspirin 
hydrolytic activity. It is the first time that blood aspirin hydrolases have been 
identified and characterized. The relationship between blood aspirin hydrolases and 
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aspirin efficacy was investigated. Both plasma and erythrocytes significantly 
modulated aspirin efficacy, and they varied in parallel with aspirin hydrolytic activity. 
These findings may explain one cause of the phenomenon of aspirin resistance. These 
also provided personalized medicine of aspirin valuable data. 
Aspirin prophylaxis suppresses major adverse cardiovascular events, but its 
turnover in blood is rapid, which limits its inhibition effects on platelet 
cyclooxygenase and thrombosis. Attention has focused on a phenomenon of aspirin 
ineffectiveness where not all individuals or populations appear to receive the full 
prophylactic or therapeutic benefits of aspirin (Williams, Asad et al. 1987; Akopov, 
Grigorian et al. 1992; Puche, Gomez-Valverde et al. 1993; Gresner, Dolnik et al. 2006; 
Kotani, Kimura et al. 2010). Inter-individual variability of platelet responses to aspirin 
clinically presents as treatment failure, and this increasing clinical phenomenon is 
frequently named aspirin “resistance”. The physiologic basis for this aspirin resistance 
is undefined, and even whether the phenomenon is real or documentable is debated 
(Patrono and Rocca 2007). Despite these clinical and laboratory issues, variation in 
the time aspirin circulates will affect its ability to inactivate cyclooxygenase 1 and 
inhibit platelet function. Aspirin turnover limits its effectiveness, so the enzyme(s) 
responsible for this hydrolysis is important. Aspirin hydrolysis was not subjected to 
natural selection, and so must be a property of enzymes selected in other ways. 
Accordingly, several esterases have the ability to hydrolyze aspirin that include 
uridine diphosphate glucuronyl transferase (Bigler, Whitton et al. 2001; Chan, Tranah 
et al. 2005), carboxylesterase 2 (Mentlein and Heymann 1984; Yamaori, Fujiyama et 
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al. 2006), and undefined activities distinct from cholinesterases and nonspecific 
carboxyesterases (Ali and Kaur 1983). However, the enzymes that actually contribute 
to aspirin turnover in blood need to be defined to better understand aspirin resistance. 
In my thesis, I defined blood aspirin hydrolases by purifying them, and I found 
large variation of this activity among individuals. This may be one of many possible 
reasons that explain aspirin “resistance”. From point of pharmacokinetic view, 
insufficient bioavailability, could be more reasonable and fundamental to explain 
“aspirin resistance” because of aspirin’s short half-life (15-20min) and low dose usage 
(75-81mg/day). Higher aspirin hydrolytic activity would reduce its bioavailability. 
Clinical evidence is that a fixed lower dose aspirin was not enough to completely 
inhibit platelet aggregation in all individuals, but higher dose of aspirin can achieve 
complete inhibition of platelet aggregation (Helgason, Bolin et al. 1994). Higher dose 
of aspirin (325mg/day) were found better than lower dose (ten Berg, Gerritsen et al. 
2002; Lim, Ali et al. 2003) and could overcome “aspirin resistance” both in patients 
and healthy volunteers, although deleterious side effect may occur, such as gut 
bleeding (Serebruany, Steinhubl et al. 2005). Actually, patients with high aspirin 
hydrolytic activity may lead to “aspirin resistance”, while patients with low aspirin 
hydrolytic activity may be prone to have bleeding problem (Gorelick and Weisman 
2005). “Aspirin resistance” may be more predominant because low dose aspirin is 
commonly used. Optimal dosage of aspirin should be personalized (He, Whelton et al. 
1998; 2010). 
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The final aim in medicine will be Personalized Medicine. There are always 
different requirements or reactions of patients to certain medicine or therapies. 
However, in Evidence Based Medicine (EVB), the current format of medicine, the 
doses of drug needed to treat patients are based on average treatment effects, which 
are fixed as a golden standard.  In the other word, we treat one patient by using 
experiences from other patients. This experiences or data from studying group of 
population are applied to statistical models, which are used to evaluate certain risks 
and to make certain baseline to determine the “personalized” probability of benefit. 
However, the overall average degree of benefit for a statistical models is often more 
than that in any typical patient needs to be treated (Kent and Hayward 2007).  The 
proposed baseline risk, which determines the benefits of patients, is usually highly 
skewed. So only a few high-risk patients, but not most patients, may have the power 
to determine most of the benefit and baseline risks (Ioannidis and Lau 1997). This 
situation is remarkable, when the overall risk of the outcome of interest is low. To 
avoid this kind of disadvantage, we need to change population-based analysis to 
individualized decision-making personalized medicine, which can apply an 
individual's unique biological information to optimize individual medical care. It is 
straightforward, but its implementation remains challenging.  
The rising of pharmacogenetics makes personalized medicine possible and 
more reality by improving all aspects of its process. Pharmacogenetics refers to 
science dealing with how genetic variation can alter an individual’s response to a 
certain therapy and medication or modify pharmacological properties of a certain drug. 
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This new field is a bridge which connects genetics to pharmacology. If genetic 
information is applied to genotype-specific investigations or incorporated into clinical 
trials successfully, we may be able to identify patients who would obtain the greatest 
overall benefit from the medication or therapy and accelerate process of drug 
development. For example, advances in pharmacogenomics of vascular biology have 
been applied to medical therapy of an individual's vascular diseases successfully 
(Degoma, Rivera et al. 2011). 
As a part of cardiovascular medicine, oral anti-platelet therapy needs to be 
personalized. To understand and to perform personalized patient care in 
cardiovascular diseases, pharmacogenetics becomes more important in anti-platelet 
therapy field. However, genetic testing used to predict patient’s response to various 
anti-platelet therapies and to determine drug or dose selection is more far from routine 
clinical use, although widely acknowledgement of it. However, pharmacogenetic-
based selection of anti-platelet therapy will be supported by ongoing and future 
clinical trials, which provide the valuable evidence and data. 
Aspirin as an established anti-platelet therapy is the therapeutic milestone for 
the prophylaxes of cardiovascular diseases in patients (Smith, Allen et al. 2006; Bhatt 
2007). Aspirin irreversibly inactivates the cyclooxygenase-1 (COX-1) in platelets 
which cannot convert arachidonic acid to prostaglandin G2 (PGG2), blocking 
thromboxane A2 (TXA2) production, and then inhibits platelet activation. It is widely 
believed benefits of aspirin for primary CVD prevention are dependent on a patient’s 
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baseline risk of CVD. However, therapeutic efficacy of aspirin varies between 5% and 
60% depending on the population and methodology used (Gum, Kottke-Marchant et 
al. 2001; Patrono 2003; Gorog, Sweeny et al. 2009), namely ‘aspirin resistance’ which 
is highly controversial. A common understanding of aspirin resistance is that normal 
therapeutic amount of aspirin cannot inhibit platelet activation (Faraday, Yanek et al. 
2007).  Tests that directly measure COX-1 inhibition demonstrated 81 mg aspirin per 
day is adequate. But because of insufficient aspirin dosing and non-compliance, the 
so-called “resistance” might also occur in COX-1-dependent anti-platelet function of 
aspirin (Faraday, Becker et al. 2007; Faraday, Yanek et al. 2007) (Gurbel, Bliden et al. 
2007). However, platelet agonists such as collagen, adenosine diphosphate (ADP), 
epinephrine, and thrombin, which may act via COX-1 independent pathways also 
results numerous biological heritability and variability in aspirin treated platelets 
(Faraday, Yanek et al. 2007; Gurbel, Bliden et al. 2007). Also in aspirin-treated 
patients, arachidonic acid (AA) still can induce platelet activation, which suggested 
via COX-independent pathways of platelet aggregation (Frelinger, Furman et al. 
2006). All these indicate that platelet activation is a complicated event. Patients 
receiving therapeutic doses of aspirin still can suffer in severe cardiovascular events, 
which raised the issue of aspirin resistance (Maree, Curtin et al. 2005; Wang, Bhatt et 
al. 2006). To reveal the mechanism behind this, Sussman et al concluded that a single 
threshold for aspirin is inappropriate (Pearson, Blair et al. 2002; 2009). So to decide 
the right doses of aspirin a patient should take requires a robust and realistic 
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discussion of correlation between patients and drugs, including not only 
pharmacology but also the individualized risk assessment for CVD of patients. 
All my work has been here provides not only basic molecular mechanisms of 
aspirin resistance, but also valuable pharmacogenetics data of aspirin metabolism. 
This is the first step from traditional EVB of aspirin to its personalized therapeutics. 
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